

PERSONAL INFORMATION

Family name Nodari
Name Savina
Date of birth [REDACTED]
Citizenship Italian

EDUCATION

Degree at the University of Brescia: 10/24/1984
Degree, Medical Doctor
Discipline, Medicine

GRADUATE MEDICAL EDUCATION

1982 – 1984 Internship, Institute of Cardiology, Spedali Civili Hospital, University of Brescia, Italy
1984 – 1989 Fellowship in cardiology, Institute of Cardiology, Spedali Civili Hospital, University of Brescia, Italy
Since 1989 Cardiologist at the University of Brescia and Spedali Civili Hospital of Brescia, Italy

BOARD CERTIFICATION and MEDICAL LICENSURE

Registered as Medical Doctor in Brescia since 02/14/1985
Cardiologist since 1989

FACULTY APPOINTMENTS

- 10/29/2003: Associate Professor of Cardiology at the University of Brescia, Italy
- 11/01/2008-10/31/2010 Visiting Professor c/o Northwestern University Feinberg School of Medicine- Bluhm Cardiovascular Institute, Northwestern Memorial Hospital, Chicago, IL (USA)
- 11/01/2010-04/30/2011 Visiting Professor c/o Northwestern University Feinberg School of Medicine. 'Center for Cardiovascular Innovation' Chicago, IL (USA)
- 08/01/2011-08/31/2011 Visiting Professor c/o Northwestern University Feinberg School of Medicine. 'Center for Cardiovascular Innovation' Chicago, IL (USA)
- National Abilitation for Full Professor in Cardiovascular Diseases (August 4th 2017)

HOSPITAL APPOINTMENTS

- From 1989 to 1992 Medical Doctor in the Section of Cardiac Rehabilitation of Spedali Civili of Brescia
- From 1992 to 2000 Medical Doctor in the Section of Cardiac Clinical and non invasive evaluation of Spedali Civili of Brescia
- Since 2000 Director of Heart Failure Unit and Day Hospital of Heart Failure and Arrhythmias, Department of Cardiology and Cardiothoracic Surgery, Spedali Civili Hospital of Brescia. Department of Clinical and Surgical Specialities, Radiological Sciences and Public Health University of Brescia Medical School, Italy.

CLINICAL AND ASSISTANCE SKILLS

During the first period at the Cardiological Rehabilitation Section of the Spedali Civili, from 11/28/1989 to 31 August 1992, I have improved my skills in the non-invasive evaluation and in the management and rehabilitation of the post-surgical valvular and coronary patients, patient with recent IMA and patient with chronic heart failure.

From 1/9/92 to 26/6/2000 at the Policardiography Service of the Spedali Civili of Brescia, I improved my knowledge in the non-invasive cardiological diagnostic techniques, including nuclear imaging techniques. In particular, during this period I have improved my skills in the assessment and management of cardiac patients admitted to the wards of surgical and medical internship, in the management of the pre and postoperative period, in the clinical cardiological evaluations of patients admitted to Emergency Department or Intensive Care Unit.

Since 27/06/2000 I have carried out and performed assistance at the Cardiology Department, as head of section A of the inpatient ward, improving my skills in the acute and post-acute patient management.

From 27/06/2000 to date, I am Head of the Day Hospital for Heart Failure and Arrhythmias Unit, aimed at the management and follow-up of cardiological patients, the management of patients with unstable or advanced heart failure or awaiting heart transplantation, with the need for infusion therapy or diagnostic-therapeutic procedures, requiring clinical and instrumental monitoring; patients candidates for TAVI procedures, mitral clips application or ICD, CRT or other devices implantation; management and treatment of AF by ECV; clinical and instrumental evaluations for heart transplantation (including cardiopulmonary and right-heart catheterization test).

COMMITTEE SERVICE

Since 2007 Member of Ethical Committee of University and Spedali Civili Hospital of Brescia

PROFESSIONAL SOCIETY MEMBERSHIPS

- Member of the European Society of Cardiology
- Member of the Heart Failure Association of the European Society of Cardiology
- Member of the Working Group on Coronary Pathophysiology and Microcirculation of the European Society of Cardiology
- Fellow of the European Society of Cardiology (FESC)
- Fellow of the Heart Failure Association of the European Society of Cardiology (FHFA)
- Member of Italian Society of Echocardiography
- Member of Italian Chapter of International Society of Cardiac Ultrasound (ICISCU)
- Member of the Italian Society of Cardiology since 1984
- Chairman of the Board of Working Group on Ventricular Function of the Italian Society of Cardiology
- Member of the Working Group on Heart Failure of the Italian Society of Cardiology
- Member of the Working Group on Peripheral Circulation of Italian Society of Cardiology
- Member of the Working Group on Gender Cardiovascular Disease of Italian Society of Cardiology
- Member of Working Group on Cardiotoxicity and Cardioncology
- Member of Working Group on e Health, Telemedicine

PROFESSIONAL and SCIENTIFIC SERVICE

- Secretary of the Italian Federation of Cardiology from 2007 to 2010
- Member of the Board of the Italian Society of Cardiology from 2006 to 2010 and since 2018 up to date
- Member of Board of FINSIC of Italian Society of Cardiology from 2010 to 2014 and since 2018 up to date
- President of Vigilance Committee of Italian Society of Cardiology since 2008 up to date
- Chairman of the Institutional Relations Committee on Regional Chapters of the Italian Society of Cardiology from 2006 to 2008

- Member of Board of ICISCU since 2001
- Member of Board of Regional Section of the Italian Society of Cardiology since 2004
- Member of Scientific Committee of National Health Institute for Educational Programs in Cardiovascular Disease since 2004.
- Chairman of Heart Failure Working Group of the Italian Society of Cardiology from 2014 to 2018
- Chairman of Heart Failure WG of the Italian Federation of Cardiology from 2016 to 2019

Management or participation in editorial committees of magazines, series of editorials, encyclopedias and treaties of recognized prestige

- Review activities for: European Journal of Heart Failure, American Journal of Cardiology, Heart Failure Reviews, Journal of Cardiovascular Medicine, Heart International, Italian Heart Journal, Italian Journal of Echocardiography, JACC, Circulation
- Journal of Cardiovascular Medicine – Associate Editor. Since 01/11/2012
- Associate Editor of the Scientific Journal “Heart International” (Wichtig Editore - Milano/Birmingham/Osaka) from 2005 to 2009
- Associate Editor of the European Journal of Heart Failure up to date

TEACHING

Teaching of doctoral and post-doctoral students and thesis supervision

- From 1985 to 1989: Professor of Anatomy and Human Physiology at the Nursing School, University of Brescia.
- Since 2002 to 2012: Professor of Cardiology at the School of Radiologic Imaging and Radiotherapy, University of Brescia.
- From 1989 up to date: Professor of Cardiology at the Nursing School, University of Brescia.
- Since 1997: Professor at the Postgraduate School of Cardiovascular Diseases, University of Brescia
- Since 1998: Professor and Coordinator of Cardiology at the School of Physiotherapy, University of Brescia.
- Since 2003: Professor of Cardiology at the School of Medicine, University of Brescia.
- Since 2005: Professor of Cardiology at the Motor Sciences Studies School, University of Brescia.

Teaching in a clinical setting and thesis supervision

- Since 1989 tutor of doctoral students, residents, post-doctoral students and fellows in cardiology in a clinical setting
- Since 1996 thesis supervisor in a research setting for medical doctors, fellows in Cardiology and fellows in Physical Rehabilitation School of the University of Brescia (until now over 200)

International Master Program

CO-Director International Master Level II - Global Research Training Program in Drug Development for Heart Failure

<http://www.unibs.it/didattica/master-corsi-di-perfezionamento-e-summer-school/master/global-research-training-program-drug-development-heart-failure-aa-2014/2015>

since 01-10-2015 to 26-11-2018.

Doctorate Research Program (Ph D)

Teacher Doctorate Research Program - Biomedical Sciences and Translational Medicine - University of Brescia since 2013 up to date.

Member of Scientific Committee of Update Courses for cardiologists (course director Prof. Livio Dei Cas – Department of Cardiology, University of Brescia, Italy): Since 1989 to 2017 – main focuses:

- Myocardial Ischemia,
 - Heart Failure,
 - Acute Myocardial Infarction,
 - Hypertensive cardiomyopathy,
 - Cardomyopathies,
 - Clinical pharmacology and cardiovascular therapy,
 - Pathophysiology to new therapeutic options for Heart Failure,
 - Endothelial function, acute coronary syndromes and pulmonary embolism,
 - Ischemic Cardiopathy, Heart Failure and Arrhythmias: recent advances in physiopathology, clinical setting and medical-surgical therapy,
 - Acute Heart Failure and others Cardiovascular Emergencies: Progress in physiopathology and therapy.
-

Teaching in continuing education courses and up-date in cardiology, endorsed by the Italian Society of Cardiology

- 1997 Up-date in Heart Failure physiopathology and therapy. Theoric/practice course for cardiologists.
- 1998 Up-date in Ischemic and valvular cardiac disease. Theoric/practice course for cardiologists.
- 2002 Up-date in Heart Failure physiopathology, clinical setting, and diagnosis, therapy and disease management programs of patients with chronic heart failure. Theoric/practice course for cardiologists.

Teaching in continuing education courses and up-date in cardiology, endorsed by the Italian Society of Cardiology and Working Group of Heart Failure.

- Since 2000 has developed periodic education and up-date courses regarding Heart Failure for cardiologists, general practitioners and nurses.

RESEARCH GRANTS/CONTRACTS (provide principal investigator status, funding agency, title and type of award, period of support, total direct costs)

Management or participation in activities of a research group characterized by Collaborations at national or international level

- At the time of attendance as visiting Professor at Northwestern University of Chicago, it was possible to strengthen international scientific collaborations in the field of research on heart failure that led to the realization of a research Network Engaged in the realization of studies of new molecules (phase 2 studies). The research group (**T1 Network**) is composed of international experts such as: Mihai Gheorghiade (Center for Cardiovascular Innovation, Northwestern University Feinberg School of Medicine, Chicago, USA); Robert O. Bonow (MD Goldberg Distinguished Professor of Cardiology Director Center for Cardiovascular Innovation Northwestern University Feinberg School of Medicine, Chicago) Javed Butler (MD Professor of Medicine Director, Division of Cardiovascular Medicine Co-Director, Heart Institute Stony Brook University); Robert J. Mentz (MD Assistant Professor of Medicine Director of Duke University Cooperative Cardiovascular Society Advanced Heart Failure and Cardiac Transplantation Duke University Medical Center,

Durham, North Carolina Duke Clinical Research Institute, Durham); Hani N. Sabbah (PhD, FACC, FCCP, FAHA Director of Cardiovascular Research at the Henry Ford Health System Henry Ford Hospital 2799 West Grand Boulevard Detroit); Haris Subacius (Senior Biostatistician Division of Cardiology Northwestern University, Chicago); Douglas E. Vaughan (MD Irving S. Cutter Professor and Chairman Department of Medicine Northwestern University Feinberg School of Medicine Galter Pavilion, Suite 3-150 251 East Huron Street Chicago); Andrew Ambrosy (MD Division of Cardiology Duke University Medical Center Durham, NC 27705) Stephen J. Greene (MD Division of Cardiology Duke University Medical Center Durham, NC 27705) Muthiah Vaduganathan (MD MPH Department of Medicine Massachusetts General Hospital Boston, MA 02114, USA); Naoki Sato (MD Professor and Director of Internal Medicine, Cardiology, and Intensive Care Unit, Nippon Medical School Musashi-Kosugi Hospital ,Kanagawa)Carolyn Lam Su Ping (MD Associate Professor Yong Loo Lin School of Medicine, Cardiac Department National University Heart Centre, Singapore)Voors Adriaan Alexander(Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.)Düngen Hans Dirk(Department of Cardiology, Campus Virchow, Charite Universitätsmedizin Berlin, Berlin, Germany.) Ponikowski Piotr(Wroclaw Medical University, Wroclaw, Poland.), Bax Jeroen J (Department of Cardiology, Leiden University Medical Center, Leiden, the Netherlands.), Kim Raymond J(Duke Cardiovascular Magnetic Resonance Center, Duke University Medical Center, Durham, NC, USA.), Dorhout Bernard (Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.) Since 01-01-2008.

- Project of a Research Unit - Prot.2010C7ETAJ_001. 01-01-2010 to 31-12-2011
- SEVENTH FRAMEWORK PROGRAMME THEME FP7-HEALTH-2009-single-stage [HEALTH-2009-2.4.2-1: Improved or new therapeutic approaches for the treatment of heart failure.] 01-04-2010 to 31-03-2015

Research Grants from the Italian National Research Council and from the University of Brescia:

- 2002 Effects of weight loss on left ventricular function, autonomic system and neurohormonal parameters in obese patients

- 2003-2004 Clinical and prognostic value of demographic, hemodynamic and functional features and genetic pattern in patients with left ventricular dysfunction treated with ACE -inhibitors and beta-blockers
- 2005-2006 Effects of n3-PUFAs on sympatovagal balance and arrhythmic risk in patients with chronic heart failure
- 2007-2008 Prognostic role of clinical, metabolic, angiographic parameters and pharmacological treatment in ischemic diabetic patients with normal or impaired left ventricular function
- Regional project: Experimentation of innovative models of integration between health and social service based on advanced services of Telemedicine (2007-2008)
- 2009-2010 project on Heart Failure: Innovation in Patient Care and Improving Outcomes (in collaboration with Northwestern University Feinberg School of Medicine and Northwestern Memorial Hospital
- 2011: Effects of Micronutrients supplements on Left ventricular function and exercise tolerance and outcome in patients with non-ischemic cardiomyopathy –University of Brescia
- 2012: Management model for acute chest pain – University of Brescia
- 2012: Early detection of cardiotoxicity in patients treated with antineoplastic agents for breast cancer – University of Brescia
- 2013 Early detection of cardiotoxicity in patients treated with antineoplastic agents for breast cancer – University of Brescia
- 2018: two-dimensional speckle tracking echocardiography and late gadolinium enhancement (2018-2020)

Research grant from ‘Center for the Study and treatment of Heart Failure’ – University of Brescia.

- 2006: n-3 Polyunsaturated Fatty Acids in the Prevention of Atrial Fibrillation Recurrences After Electrical Cardioversion A Prospective, Randomized Study
- 2007: Effects of n-3 Polyunsaturated Fatty Acids on Left Ventricular Function and Functional Capacity in Patients With Dilated Cardiomyopathy
- 2008-2011 Effects of air pollution on admission for acute cardiovascular events in Brescia urban area (in collaboration with Institute of Occupational Health and Industrial Hygiene - University of Brescia

- 2012: 'Effects of N-3 PUFAs supplementation on Left ventricular function and remodeling and functional capacity in patient with non-ischemic cardiomyopathy. Dose-response study'

Responsibility for studies and scientific research entrusted by qualified public or private institutions

- DHAFI STUDY -Prot. F 373280 CA 2 01 - Study of efficacy and safety of F373280 for the maintenance of sinus rhythm after electrical cardioversion in patients with persistent atrial fibrillation and chronic heart failure - Prot. F 373280 CA 2 01 - Eudract 2012-003487-48. From 01-10-2013 to 13-10-2016 (International Study Coordinator)
- PARSiFAL - BAY 1067197/16782 - Double-blind, placebo-controlled study to assess the safety, tolerability, pharmacokinetics and acute cardiovascular responses of 7-day oral treatment with the partial adenosine A1 BAY 1067197 agonist in patients with heart failure chronic systolic: PARSiFAL pilot study - PARSiFAL study - BAY 1067197/16782 - Eudract 2013-002522-23. From 28-01-2014 to 28-01-2015 (Principal Investigator)
- A Long-Term Outcomes Study to Assess SStatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs with Hypertriglyceridemia (STRENGTH) Investigational Product: Epanova® (omega-3 carboxylic acids) IND No.: 107,616 Phase: III. Protocol Number: D5881C00004. EudraCT Number: 2014-001069-28. Since 01-03-2014. (Principal Investigator)
- Phanteon Study - A multicenter, randomized, parallel group, double blind, dose-finding phase II trial to study the efficacy, safety, pharmacokinetic and pharmacodynamic effects of the oral partial adenosine A1 receptor agonist neladenoson bialanate over 20 weeks in patients with chronic heart failure with reduced ejection fraction. Since 26-08-2015. (Principal Investigator)
- Clinical monitoring and genetic screening of the cancer patient undergoing cardiotoxic treatment. Research project funded by the Beretta Foundation. From 01-11-2015 to 01-11-2017. (Principal Investigator)
- SPIHF-201 CLINICAL STUDY PROTOCOL A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Effects of Multiple Subcutaneous Injections of Elamipretide on Left Ventricular Function in Subjects with Stable Heart Failure with Reduced Ejection Fraction. Since 23-11-2015. (Principal Investigator)
- Chiara Mia 1 - BAY 1142524 / 17055 - Multicenter single-blind pilot study to assess the safety and tolerability of 14-day oral treatment with different doses of the BAY 114,324 Kinase inhibitor

compared to placebo in clinically stable patients with left ventricular dysfunction after myocardial infarction - Studio Chiara Mia 1 - BAY 1142524 / 17055 -Eudract 2014-005297-12. From 30-11-2015 to 30-11-2016. (Principal Investigator)

- BAY 1142524 - CHIARA MIA 2 - Multi-center, randomized, double-blind clinical trial aimed at assessing the safety and efficacy of a 6-month treatment with the oral chimay inhibitor BAY 1142524 at a dose of 25 mg / bid compared to placebo, in addition to standard therapy , in patients with reduced left ventricular ejection fraction (LVEF < 45%) after acute myocardial infarction (CHIARA MIA 2)- Studio BAY 1142524 - CHIARA MIA 2 – Eudract 2016-002167-33. Since 31-10-2016. (Principal Investigator)
- ETNA-AF-Europe Non-interventional study on edoxaban treatment in routine clinical practice for patients with non valvular atrial fibrillation DSE-EDO-04-14-EU. Since 01-11-2016. (Principal Investigator)
- VICTORIA-MK1242-001 - Pivotal study of Phase 3 multicenter, randomized parallel group, placebo-controlled, double-blind, event-guided, placebo-controlled studies on the efficacy and safety of the oral vericiguat sGC stimulator in patients with heart failure with a reduced ejection fraction (HFrEF) - Study VICTORIA (VerICiguaT gLOBal study in subjects with heart failure and Reduced ejection frAction) - Study VICTORIA-MK1242-001 - Eudract 2016-000671-25 from 30-11-2016 until today (Principal Investigator)
- Real Life Multimarker Monitoring in Patients with Heart Failure (REALISM-HF pilot registry) from 01-12-2016 until today (Principal Investigator)
- Multi-center, randomized, parallel group, placebo-controlled, double-blind study aimed at evaluating the efficacy and safety of the SGC vericiguat oral stimulator for the improvement of physical function in the activities of daily life in patients with heart failure and preserved ejection fraction (HFPEF) - VITALITY-HFPEF BAY study 1021189/19334 - Eudract 2018-000298-65 PROMOTER: Bayer SpA CRO: Bayer S.p.A (Principal Investigator)
- A Multicenter, Randomized, Parallel Group, Double Blind, Active and Placebo Controlled Study of BAY 1753011, a Dual V1a/V2 Vasopressin Receptor Antagonist, in Patients with Congestive Heart Failure - AVANTI Study BAY 1753011 n. IMPACT 17909/EudraCT 2018-004059-18 (Principal Investigator)

- Autonomic regulation therapy to enhance myocardial function and reduce progression of heart failure with reduced ejection fraction – ANTHEM HF rEF C-07 (Principal Investigator)
- Intravenous Iron in Patients with Systolic Heart Failure and Iron Deficiency to Improve Morbidity & Mortality (FAIR-HF2) - ClinicalTrials.gov Identifier: NCT03036462 (Principal Investigator)
- FINEARTS study BAY 20103: A multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants with heart failure (NYHA II-IV) and left ventricular ejection fraction $\geq 40\%$ (LVEF $\geq 40\%$) (National Coordinator)
- ACE2 molecule in SARS-CoV-2/COVID19 infection and its potential ACCEPT STUDY
Prognostic and Therapeutic role (Principal investigator e National Coordinator)
- Prospective analytical study for the evaluation of the effects of Covid-19 on the autonomic nervous system in patients with Post-Covid syndrome (Principal investigator e National Coordinator)
- Victor Study: A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulator Vericiguat/MK-1242 in Adults With Chronic Heart Failure With Reduced Ejection Fraction (Principal investigator e National Coordinator)

SCHOLARLY BIBLIOGRAPHY

Original, peer-reviewed research articles

1. Metra M, Faggiano P, Giubbini R, Manca C, Marchini A, Niccoli L, **Nodari S**, Zanini R, Dei Cas L. Evaluation of asynergy of the left ventricle in infarct patients. A comparative analysis of 2-dimensional echocardiography, angio-cardio-scintigraphy and contrast media ventriculography *Cardiologia*. 1986 Apr;31(4):273-8.
2. Dei Cas L, Ghirardi P, Metra M, **Nodari S**, Nordio G, Mussini E. Comparative pharmacokinetics of a new slow release and standard prazosin in healthy subjects. *Curr Ther Res*, 1986; 40: 17-22
3. Dei Cas L, Metra M, Danesi R, **Nodari S**, Guaini T, Raddino R, Ghirardi PE. Steady state pharmacokinetics of a new slow release-preparation of prazosin. *Curr Ther Res*, 1988; 44 (2): 275-277.
4. Metra M, **Nodari S**, Nordio G, Bonandi L, Raddino R, Feroldi P, Dei Cas L, Visioli O. A randomized double-blind crossover study of nicardipine and nifedipine in patients with angina pectoris and concomitant essential hypertension. *Cardiovasc Drugs Ther*. 1988 Jan;1(5):513-21.

5. Dei Cas L, Metra M, **Nodari S**, Riva S, Manca C, Visioli O. Lack of tolerance development during chronic ibopamine administration to patients with congestive heart failure. *Cardiovasc Drugs Ther.* 1988 Jul;2(2):221-9.
6. Furlanello F, Auguglia C, Brandi F, Brusoni B, Cadel A, Caponetto S, Dei Cas L, Gavazzi A, Guiducci V, Mangiavacchi M, Martines C, Metra M, **Nodari S**, Terrachini U, Tumiotta G. Influence of ibopamine on heart rate and arrhythmic pattern in CHF patients: a double-blind multicenter study. *Giornale Italiano di Cardiologia* 1989; 19: 71-80.
7. Dei Cas L, Metra M, **Nodari S**, Visioli O. Efficacy of ibopamine treatment in patients with advanced heart failure: purpose of a new therapeutic scheme with multiple daily administrations. *J Cardiovasc Pharmacol.* 1989;14 Suppl 8:S111-7.
8. Dei Cas L, Metra M, Cuccia C, Niccoli L, **Nodari S**, Visioli O. Prognostic significance of clinical, ergometric and coronarographic data in patients soon after myocardial infarction. *Cardiologia* 1989 Apr;34(4):317-25.
9. Dei Cas L, Metra M, **Nodari S**, Raddino R, Visioli O. Hemodynamic and clinical effects and treatment tolerance with low-dose iv amrinone in patients with refractory heart failure: a multicenter study. The Group for Research on Amrinone in the Treatment of Refractory Heart Failure. *Cardiologia* 1991 May;36(5):363-71.
10. **Nodari S**, Metra M, Gei P, Danesi R, Furloni R, Cuminetti S, Dei Cas L. The acute, chronic continuous after treatment and chronic intermittent with a variable therapeutic window (4 and 6 hours) hemodynamic effects induced with transdermal nitroglycerin in patients with congestive heart failure. *Cardiologia* 1991 Jun;36(6):451-60.
11. Raddino R, Metra M, Catellani E, **Nodari S**, Pelà G, Manca C, Dei Cas L. Effects of amrinone on isolated heart preparations: comparative study with other inotropic agents. *Cardiologia* 1991 Sep;36(9):729-34.
12. Dei Cas L, Metra M, **Nodari S**, Raddino R, Bonandi L, Visioli O. Treatment of refractory heart failure. *Cardiologia.* 1992 Jul;37(7):501-5. Review.
13. Bonandi L, Metra M, Niccoli L, Etori F, **Nodari S**, Dei Cas L, Visioli O. Combined invasive and noninvasive study of left ventricular systolic and diastolic function following acute administration of cicloprolol to subjects with normal cardiac function. *Cardiovasc Drugs Ther.* 1992 Oct;6: 513-517.
14. Dei Cas L, Metra M, **Nodari S**, Leier CV, Visioli O. Interaction between electrolytes and the neurohumoral system. The clinico-prognostic implications of hyponatremia, hypopotassemia and hypomagnesemia in congestive heart failure. *Cardiologia* 1993 Jun;38(6):393-402. Review.
15. Dei Cas L, Metra M, **Nodari S**, Visioli O. Treatment strategies in acute heart failure: how to restore hemodynamic stability rapidly and safely. *Cardiologia* 1993 Sep;38(9):593-9. Review.

16. Dei Cas L, Metra M, **Nodari S**, Nardi M, Giubbini R, Visioli O. Stress and ischemic heart disease. *Cardiologia* 1993 Dec;38(12 Suppl 1):415-25. Review.
17. Dei Cas L, **Nodari S**, Raddino R, Metra M, Pelà G, Nardi M. Current role of non-digitalis inotropic agents in acute and chronic treatment of heart failure. *Cardiologia* 1994 Mar;39(3):209-15. Review.
18. Dei Cas L, Metra M, **Nodari S**, Raccagni D. Clinical efficacy of oral dopaminergic agents: new findings. *Cardiologia* 1995 Dec;40 (12 Suppl 1):131-8.
19. Raddino R, Metra M, **Nodari S**, Pelà G, Fappani A, Dei Cas L. Pharmacological activity of the new calcium antagonist, lacidipine, on isolated preparations. *Gen Pharmacol.* 1996 Oct;27(7):1255-9.
20. Metra M, **Nodari S**, Garbellini M, Boldi E, Rosselli F, Milan E, Giubbini R, Dei Cas L. The effects of mid- and long-term administration (3-4 years) of carvedilol in patients with idiopathic dilated cardiomyopathy. *Cardiologia* 1997 May;42(5):503-12.
21. Metra M, **Nodari S**, Raccagni D, Garbellini M, Boldi E, Bontempi L, Gaiti M, Dei Cas L. Maximal and submaximal exercise testing in heart failure. *J Cardiovasc Pharmacol.* 1998;32 Suppl 1:S36-45. Review.
22. Metra M, **Nodari S**, D'Aloia A, Madureri A, Rosselli F, Bontempi L, Zanini R, Dei Cas L. Effects of neurohormonal antagonism on symptoms and quality-of-life in heart failure. *Eur Heart J.* 1998 Feb;19 Suppl B: B25-35. Review.
23. Zanini R, Curello S, Bonandi L, Giovannini G, Boldi E, D'Aloia A, Metra M, **Nodari S**, Dei Cas L. Etiopathogenesis of acute myocardial infarction: role of early leukocytosis. *Cardiologia* 1998 Sep;43(9):925-31.
24. Metra M, Faggiano P, D'Aloia A, **Nodari S**, Gualeni A, Raccagni D, Dei Cas L. Use of cardiopulmonary exercise testing with hemodynamic monitoring in the prognostic assessment of ambulatory patients with chronic heart failure. *J Am Coll Cardiol.* 1999 Mar 15;33(4):943-50.
25. Metra M, **Nodari S**, Bordonali T, Cagnazzi E, Boldi E, Dei Cas L. ACE-inhibitors, AT1 receptor antagonists and diastolic dysfunction. *Cardiologia* 1999 Dec;44 Suppl 1(Pt 1):53-8. Review.
26. Metra M, **Nodari S**, D'Aloia A, Bontempi L, Boldi E, Cas LD. A rationale for the use of beta-blockers as standard treatment for heart failure. *Am Heart J.* 2000 Mar;139(3):511-21. Review.
27. Metra M, **Nodari S**, Boldi E, Dei Cas L. Selective or nonselective beta-adrenergic blockade in patients with congestive heart failure. *Curr Cardiol Rep.* 2000 May;2(3):252-7.
28. Metra M, Giubbini R, **Nodari S**, Boldi E, Modena MG, Dei Cas L. Differential effects of beta-blockers in patients with heart failure: A prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol. *Circulation* 2000 Aug 1;102(5):546-51.

29. Metra M, Giubbini R, **Nodari S**, Boldi E, Modena MG, Dei Cas L. b-blockade in chronic heart failure. *Response Circulation* 2001; 103 e 118.
30. Metra M, **Nodari S**, Dei Cas L. Beta-blockade in heart failure: selective versus nonselective agents. *Am J Cardiovasc Drugs* 2001;1(1):3-14. Review.
31. Boglioni FV, Metra M, Locati M, **Nodari S**, Bontempi L, Garbellini M, Doni A, Peri G, Mantovani A. Role of inflammation mediators in the pathogenesis of heart failure. *Ital Heart J Suppl.* 2001 Jun;2(6):628-33. Review.
32. Metra M, **Nodari S**, Bignotti T, Gnesin P, Trussardi E, Cas LD. New and old beta-blockers in the treatment of heart failure. *Recenti Prog Med.* 2002 Feb;93(2):113-24. Review.
33. Metra M, **Nodari S**, Trussardi E, Vizzardi E, Cas LD. Dilated cardiomyopathy: indication and role of invasive evaluation. *Ital Heart J Suppl.* 2002 Apr;3(4):412-8. Review.
34. Metra M, **Nodari S**, Dei Cas L. Heart failure: should treatment favor prognosis or quality of life? Opinion... in favor of prognosis. *Ital Heart J.* 2002 Oct;3 Suppl 6:47S-50S. Review.
35. Metra M, **Nodari S**, D'Aloia A, Muneretto C, Robertson AD, Bristow MR, Dei Cas L. Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol. *J Am Coll Cardiol.* 2002 Oct 2;40(7):1248-58.
36. Metra M, **Nodari S**, Parrinello G, Giubbini R, Manca C, Dei Cas L. Marked improvement in left ventricular ejection fraction during long-term beta-blockade in patients with chronic heart failure: clinical correlates and prognostic significance. *Am Heart J.* 2003 Feb;145(2):292-9.
37. Muneretto C, Negri A, Bisleri G, Manfredi J, Terrini A, Metra M, **Nodari S**, Cas LD. Is total arterial myocardial revascularization with composite grafts a safe and useful procedure in the elderly? *Eur J Cardiothorac Surg.* 2003 May;23(5):657-64.
38. Dei Cas L, Metra M, **Nodari S**, Dei Cas A, Gheorghide M. Prevention and management of chronic heart failure in patients at risk. *Am J Cardiol.* 2003 May 8;91(9A):10F-17F. Review.
39. D'Aloia A, Faggiano P, Aurigemma G, Bontempi L, Ruggeri G, Metra M, **Nodari S**, Dei Cas L. Serum levels of carbohydrate antigen 125 in patients with chronic heart failure: relation to clinical severity, hemodynamic and Doppler echocardiographic abnormalities, and short-term prognosis. *J Am Coll Cardiol.* 2003 May 21;41(10):1805-11.
40. Vizzardi E, **Nodari S**, Fiorina C, Procopio R, Trussardi E, D'Aloia A, Rocca P, Metra M, Dei Cas L. Prognostic evaluation in patients with heart failure. *Ital Heart J Suppl.* 2003 Sep;4(9):720-6. Review.

41. Covolo L, Gelatti U, Metra M, Donato F, **Nodari S**, Pezzali N, Dei Cas L, Nardi G. Angiotensin-converting-enzyme gene polymorphism and heart failure: a case-control study. *Biomarkers* 2003 Sep-Oct;8(5):429-36.
42. Muneretto C, Bisleri G, Negri A, Manfredi J, Metra M, **Nodari S**, Dei Cas L. Off-pump coronary artery bypass surgery technique for total arterial myocardial revascularization: a prospective randomized study. *Ann Thorac Surg.* 2003 Sep;76(3):778-82.
43. Muneretto C, Bisleri G, Negri A, Manfredi J, Metra M, **Nodari S**, Culot L, Dei Cas L. Total arterial myocardial revascularization with composite grafts improves results of coronary surgery in elderly: a prospective randomized comparison with conventional coronary artery bypass surgery. *Circulation* 2003 Sep 9;108 Suppl 1: II29-33.
44. **Nodari S**, Metra M, Dei Cas L. Beta-blocker treatment of patients with diastolic heart failure and arterial hypertension. A prospective, randomized, comparison of the long-term effects of atenolol vs. nebivolol. *Eur J Heart Fail.* 2003 Oct;5(5):621-7.
45. Metra M, **Nodari S**, Pedrinazzi C, Rocca P, Manerba A, Vizzardi E, Danesi R, Dei Cas L. Plasma brain natriuretic peptide levels in the diagnostic and prognostic assessment of patients with heart failure. *Pros. Ital Heart J.* 2003 Dec;4 Suppl 8:59S-67S. Review.
46. **Nodari S**, Metra M, Dei Cas A, Dei Cas L. Efficacy and tolerability of the long-term administration of carvedilol in patients with chronic heart failure with and without concomitant diabetes mellitus. *Eur J Heart Fail.* 2003 Dec;5(6):803-9.
47. Lugari R, Dei Cas A, Ugolotti D, Barilli AL, Camellini C, Ganzerla GC, Luciani A, Salerni B, Mittenperger F, **Nodari S**, Gnudi A, Zandomeneghi R. Glucagon-like peptide 1 (GLP-1) secretion and plasma dipeptidyl peptidase IV (DPP-IV) activity in morbidly obese patients undergoing biliopancreatic diversion. *Horm Metab Res.* 2004 Feb;36(2):111-5.
48. Metra M, **Nodari S**, Dei Cas L. Current guidelines in the pharmacological management of chronic heart failure. *J Renin Angiotensin Aldosterone Syst.* 2004 Sep;5 Suppl 1:S11-6. Review.
49. Covolo L, Gelatti U, Metra M, **Nodari S**, Piccichè A, Pezzali N, Zani C, Alberti A, Donato F, Nardi G, Dei Cas L. Role of beta1- and beta2-adrenoceptor polymorphisms in heart failure: a case-control study. *Eur Heart J.* 2004 Sep;25(17):1534-41.
50. Sabbadini G, Di Lenarda A, Metra M, **Nodari S**, Moretti M, Brentana L, Dei Cas L, Sinagra G. Pharmacological therapy of chronic heart failure in the elderly. *Ital Heart J.* 2004 Dec;5 Suppl 10:37S-51S. Review.
51. **Nodari S**, Metra M, Trussardi E, Madureri A, Manerba A, Sacchetti E, Dei Cas L. Cardiovascular and neurohumoral effects of the administration of reboxetine to health volunteers. *Heart International* 2005; 1 (4-8): 59-66.

52. Metra M, **Nodari S**, Brentana L, Vizzardi E, Rocca P, Fracassi F, Danesi R, Dei Cas L. Beta-blockers in the treatment of heart failure. *Ital Heart J.* 2005 May;6 Suppl 2:46S-52S.
53. **Nodari S**, Corulli A, Manerba A, Metra M, Apostoli P, Dei Cas L. Endothelial damage due air pollution. *Heart International* 2006; 2: 115-126.
54. Muneretto C, Bisleri G, Negri A, Piccoli P, **Nodari S**, Dei Cas L. Improved graft patency rates and mid-term outcome of diabetic patients undergoing total arterial myocardial revascularization. *Heart Int.* 2006;2(3-4):136.
55. Vizzardi E, **Nodari S**, Metra M, Dei Cas L. Non-compaction of the ventricular myocardium. *Heart Int.* 2006;2(3-4):178.
56. Faggiano P, D'Aloia A, Antonini-Canterin F, Pinamonti B, Di Lenarda A, Brentana L, Metra M, **Nodari S**, Dei Cas L. Usefulness of cardiac calcification on two-dimensional echocardiography for distinguishing ischaemic from nonischaemic dilated cardiomyopathy: a preliminary report. *J Cardiovasc Med (Hagerstown).* 2006 Mar;7(3):182-7.
57. Metra M, Zani C, Covolo L, **Nodari S**, Pezzali N, Gelatti U, Donato F, Nardi G, Dei Cas L. Role of beta1- and alpha2c-adrenergic receptor polymorphisms and their combination in heart failure: a case-control study. *Eur J Heart Fail.* 2006 Mar;8(2):131-5.
58. **Nodari S**, Manerba A, Berlinghieri N, Milesi G, Metra M, Dei Cas L. Nitrates: new insights about old drugs. *Heart International* 2007; 3 3-4: 69-77.
59. Dei Cas L, Metra M, **Nodari S**, Raddino R. Rationale for the use of high dose sustained-release isosorbide-5mononitrate in ischemic heart disease and chronic heart failure. *Heart International* 2007; 3 3-4: 98-111.
60. Metra M, **Nodari S**, Bordonali T, Bugatti S, Fontanella B, Lombardi C, Saporetti A, Verzura G, Danesi R, Dei Cas L. Anemia and heart failure: a cause of progression or only a consequence? *Heart International* 2007; 3 (1-2): 1-11.
61. **Nodari S**, Rocca P, Saporetti A, Bettari L, Foresti A.L, Tanghetti E, Metra M, Dei Cas L. The combination of ezetimibe and Statin: a new treatment for hypercholesterolemia. *Heart International* 2007; 3 (1-2): 12-17.
62. Raddino R, Caretta G, Teli M, Bonadei I, Robba D, Zanini G, Madureri A, **Nodari S**, Dei Cas L. Nitric oxide and cardiovascular risk factors. *Heart International* 2007; 3 (1-2): 19-26.
63. **Nodari S**, Manerba A, Metra M, Dei Cas L. Endocannabinoids and cardiovascular prevention: a real progress? *Heart International* 2007; 3 (1-2): 27-34.

64. Faggiano P, Vizzardi E, Pulcini E, Maffeo D, Fracassi F, **Nodari S**, Dei Cas L. The study of left ventricular diastolic function by Doppler echocardiography: the essential for the clinician. *Heart International* 2007; 3 (1-2): 42-50.
65. Vizzardi E, **Nodari S**, Fiorina C, Metra M, Dei Cas L. Plasma homocysteine levels and late outcome in patients with unstable angina. *Cardiology* 2007;107(4):354-9.
66. Metra M, **Nodari S**, Bordonali T, Milani P, Fracassi F, Dei Cas L. Beta-blocker therapy of heart failure: an update. *Expert Opin Pharmacother.* 2007 Feb;8(3):289-98. Review.
67. Metra M, **Nodari S**, Bordonali T, Milani P, Dei Cas L. Clinical trials update from the World Congress of Cardiology 2006. *Expert Opin Pharmacother.* 2007 Apr;8(6):881-9.
68. Vizzardi E, **Nodari S**, Fiorina C, Metra M, Dei Cas L. Raised homocysteine plasma concentration in patients with heart failure: clinical significance. *Monaldi Arch Chest Dis.* 2007 Jun;68(2):96-102.
69. Metra M, **Nodari S**, Bordonali T, Milani P, Lombardi C, Bugatti S, Fontanella B, Verzura G, Danesi R, Dei Cas L. Bisoprolol in the treatment of chronic heart failure: from pathophysiology to clinical pharmacology and trial results. *Ther Clin Risk Manag.* 2007 Aug;3(4):569-78.
70. Metra M, **Nodari S**, Parrinello G, Specchia C, Brentana L, Rocca P, Fracassi F, Bordonali T, Milani P, Danesi R, Verzura G, Chiari E, Dei Cas L. The role of plasma biomarkers in acute heart failure. Serial changes and independent prognostic value of NT-proBNP and cardiac troponin-T. *Eur J Heart Fail.* 2007 Aug;9(8):776-86.
71. Fiorina C, Vizzardi E, Lorusso R, Maggio M, De Cicco G, **Nodari S**, Faggiano P, Dei Cas L. The 6-min walking test early after cardiac surgery. Reference values and the effects of rehabilitation programme. *Eur J Cardiothorac Surg.* 2007 Nov;32(5):724-9.
72. Vizzardi E, Lanzarotto F, Carabellese N, Mora A, Bertolazzi S, Benini F, **Nodari S**, Dei Cas L, Lanzini A. Lack of association of coeliac disease with idiopathic and ischaemic dilated cardiomyopathies. *Scand J Clin Lab Invest.* 2008;68(8):692-5.
73. Metra M, **Nodari S**, Parrinello G, Bordonali T, Bugatti S, Danesi R, Fontanella B, Lombardi C, Milani P, Verzura G, Cotter G, Dittrich H, Massie BM, Dei Cas L. Worsening renal function in patients hospitalised for acute heart failure: clinical implications and prognostic significance. *Eur J Heart Fail.* 2008 Feb;10(2):188-95.
74. Vizzardi E, Fracassi F, Nardi M, Chiari E, Faggiano P, Rocca P, **Nodari S**, Dei Cas L. Asymptomatic quadricuspid aortic valve. *Can J Cardiol.* 2008 Feb;24(2):8.
75. Metra M, Zacá V, **Nodari S**, Cas LD, Maggioni AP. The CORONA study. *G Ital Cardiol.* 2008 Apr;9(4):229-33.

76. Vizzardi E, Fracassi F, Farina D, Nardi M, D'Aloia A, Chiari E, **Nodari S**, Dei Cas L. Persistence of left superior vena cava, absence of coronary sinus and cerebral ictus. *Int J Cardiol*. 2008 May 23;126(2):e39-41.
77. Vizzardi E, D'Aloia A, Zanini G, Antonioli E, Chiari E, Fiorina C, Raddino R, **Nodari S**, Dei Cas L. Coronary artery fistula: diagnostic role of transthoracic and transesophageal echocardiography. *Minerva Cardioangiol*. 2008 Jun;56(3):361-4.
78. Dei Cas L, Metra M, **Nodari S**, Lombardi C, Zacà V. Mechanical circulatory supports for the treatment of advanced heart failure. *G Ital Cardiol (Rome)*. 2008 Oct;9(10 Suppl 1):99S-104S.
79. Metra M, Zacà V, Lombardi C, Danesi R, Bordonali T, **Nodari S**, L. Dei Cas. Acute heart failure: clinical profiles and pathophysiology. *G Ital Cardiol (Rome)*. 2008 Oct;9(10 Suppl 1):105S-111S
80. Vizzardi E, **Nodari S**, D'Aloia A, Chiari E, Faggiano P, Metra M, Dei Cas L. CA 125 tumoral marker plasma levels relate to systolic and diastolic ventricular function and to the clinical status of patients with chronic heart failure. *Echocardiography*. 2008 Oct;25(9):955-60.
81. Vizzardi E, Faggiano P, Antonioli E, Zanini G, Chiari E, **Nodari S**, L Dei Cas. Thrombus or tumor? a case of fibroelastoma as indicated during the submission process. *Cases J*. 2009 Jan 8;2(1):31.
82. **Nodari S**, Metra M, Milesi G, Manerba A, Cesana BM, Gheorghide M, Dei Cas L. The role of n-3 PUFAs in preventing the arrhythmic risk in patients with idiopathic dilated cardiomyopathy. *Cardiovasc Drugs Ther*. 2009 Feb; 23(1):5-15.
83. Vizzardi E, Faggiano P, Chiari E, Maffeo D, Frattini S, Bellandi F, **Nodari S**, Dei Cas L. The study of left ventricular diastolic function by Doppler echocardiography: the essential for the clinician. *Monaldi Arch Chest Dis*. 2009 Mar;72(1):23-8.
84. Tavazzi L, **Nodari S**. The GISSI-HF trial. *G Ital Cardiol (Rome)*. 2009 Mar;10(3):129-34.
85. Vizzardi E, **Nodari S**, Zanini G, Manerba A, Frattini S, Madureri A, Raddino R, Dei Cas L. High sensitivity C-reactive protein: a predictor for recurrence of atrial fibrillation after successful cardioversion. *Intern Emerg Med*. 2009 Aug;4(4):309-13.
86. Leone O, Rapezzi C, Sinagra G, Angelini A, Arbustini E, Bartoloni G, Basso C, Caforio AL, Calabrese F, Coccolo F, d'Amati G, Mariesi E, Milanese O, **Nodari S**, Oliva F, Perkan A, Prandstraller D, Pucci A, Ramondo A, Silvestri F, Valente M, Thiene G; Federazione Italiana di Cardiologia. Documento di consenso sulla biopsia endomiocardica promosso dall'Associazione per la Patologia Cardiovascolare Italiana. *G Ital Cardiol (Rome)*. 2009 Sep;10(9 Suppl 1):3S-50S.
87. **Nodari S**, Jao GT, Chong JR. Clinical utility of Tolvaptan in the management of hyponatremia in HF. *International Journal of Nephrology and Renovascular Disease* 2010;3:51-60.

88. Vizzardi E, D'Aloia A, Zanini G, Fiorina C, Chiari E, **Nodari S**, Dei Cas L. Tako-tsubo-like left ventricular dysfunction: transient left ventricular apical ballooning syndrome. *Int J Clin Pract.* 2010 Jan;64(1):67-74.
89. Campia U, **Nodari S**, Gheorghide M. Acute heart failure with low cardiac output: can we develop a short-term inotropic agent that does not increase adverse events? *Current Heart Failure Reports* 2010 Sep;7(3): 100-9
90. Shah An, **Nodari S**, Gheorghide M. Biomarkers in acute heart failure syndromes-are they fulfilling their promise? *Cardiology* 2011; 120(1): 19-21.
91. Metra M, Zacà V, Parati G, Agostoni P, Bonadies M, Ciccone M, Dei Cas A, Iacoviello M, Lagoia R, Lombardi C, Maio R, Magri D, Musca G, Padeletti M, Perticone F, Pezzali N, Piepoli M, Sciacqua A, Zanolla L, **Nodari S**, Filardi PP, Dei Cas L. Cardiovascular and non cardiovascular comorbidities in patients with chronic heart failure. *Journal of Cardiovascular Medicine* 2011 Feb;12(2): 76-84.
92. **Nodari S**, Triggiani M, Campia U, Manerba A, Milesi G, Cesana BM, Gheorghide M, Dei Cas L. Effects on n-3 polyunsaturated fatty acids on left ventricular function and functional capacity in patients with dilated cardiomyopathy. *Journal of the American College of Cardiology* 2011 Feb 15;57(7):870-9.
93. Ambrosy A, Wilcox J, **Nodari S**, Gheorghide M. Acute heart failure syndromes: cardiac destruction and reconstruction. *Journal of Cardiovascular Medicine* 2011 Apr; 12(4):258-63.
94. **Nodari S**, Triggiani M, Campia U, Manerba A, Milesi G, Cesana BM, Gheorghide M, Dei Cas L. n-3 polyunsaturated fatty acids in the prevention of atrial fibrillation recurrences after electrical cardioversion: a prospective, randomized study. *Circulation.* 2011 Sep 6;124(10):1100-6.
95. **Nodari S**, Triggiani M, Manerba A, Milesi G, Dei Cas L. Effects of supplementation with polyunsaturated fatty acids in patients with heart failure. *Internal and Emergency Medicine* 2011 Oct;6(1): S37-S44
96. Palazzuoli A, Beltrami M, **Nodari S**, McCollough P, Ronco C. Clinical impact of renal dysfunction in heart failure. *Reviews in cardiovascular medicine.* 2011;12(4): 186-99.0
97. **Nodari S**, Palazzuoli A. Current treatment in acute and chronic cardio-renal syndrome. *Heart Fail Rev.* 2011 Nov;16(6):583-94
98. **Nodari S**, Manerba A, Vaccari A, Milesi G, Carubelli V, Lazzarini V, Lombardi C, Etti F, Metra M, Dei Cas A. Six-year prognosis of diabetic patients with coronary artery disease. *Eur J Clin Invest.* 2012 Apr;42(4):376-83
99. **Nodari S**, Triggiani M, Campia U, Dei Cas L. Omega-3 Polyunsaturated Fatty Acid Supplementation: Mechanism and Current Evidence in Atrial Fibrillation. *Journal of Atrial Fibrillation.* August 2012, Vol 2, Issue 12.

100. **Nodari S**, Triggiani M, Manerba A, Lupi L, Dei Cas L. Chronic heart failure therapy: where we are and where we are going to. *G Ital Cardiol*. 2012 Oct;13(10):145-51.
101. Vaduganathan M, Ambrosy AP, Greene SJ, Mentz RJ, Subacius HP, Maggioni AP, Swedberg K, **Nodari S**, Zannad F, Konstam MA, Butler J, Gheorghiade M; EVEREST trial investigators. Predictive value of low relative lymphocyte count in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial. *Circ Heart Fail*. 2012 Nov;5(6):750-8. doi: 10.1161/CIRCHEARTFAILURE.112.970525. Epub 2012 Oct 9. PMID: 23051949.
102. Sarma S, Mentz RJ, Kwasny MJ, Fought AJ, Huffman M, Subacius H, **Nodari S**, Konstam M, Swedberg K, Maggioni AP, Zannad F, Bonow RO, Gheorghiade M; on behalf of the EVEREST investigators. Association between diabetes mellitus and post-discharge outcomes in patients hospitalized with heart failure: findings from the EVEREST trial. *Eur J Heart Fail*. 2013 Feb;15(2):194-202.
103. Greene SJ, Vaduganathan M, Lupi L, Ambrosy AP, Mentz RJ, Konstam MA, **Nodari S**, Subacius HP, Fonarow GC, Bonow RO, Gheorghiade M; EVEREST Trial Investigators. Prognostic significance of serum total cholesterol and triglyceride levels in patients hospitalized for heart failure with reduced ejection fraction (from the EVEREST Trial). *Am J Cardiol*. 2013 Feb 15;111(4):574-81.
104. Dini FL, Guarini G, Ballo P, Carluccio E, Maiello M, Capozza P, Innelli P, Rosa GM, Palmiero P, Galderisi M, Razzolini R, **Nodari S**; Working Group on Myocardial Function of the Italian Society of Cardiology. The left ventricle as a mechanical engine: from Leonardo da Vinci to the echocardiographic assessment of peak power output-to-left ventricular mass. *J Cardiovasc Med (Hagerstown)*. 2013 Mar;14(3):214-20. doi: 10.2459/JCM.0b013e32834ae7fe. PMID: 21934524.
105. Gheorghiade M, Vaduganathan M, Ambrosy A, Böhm M, Campia U, Cleland JG, Fedele F, Fonarow GC, Maggioni AP, Mebazaa A, Mehra M, Metra M, **Nodari S**, Pang PS, Ponikowski P, Sabbah HN, Komajda M, Butler J. Current management and future directions for the treatment of patients hospitalized for heart failure with low blood pressure. *Heart Fail Rev*. 2013 Mar;18(2):107-22.
106. Gheorghiade M, **Nodari S**. Hospitalizations for heart failure. Preface. *Heart Fail Clin*. 2013 Jul;9(3):xi-xii.
107. Greene SJ, Gheorghiade M, Vaduganathan M, Ambrosy AP, Mentz RJ, Subacius H, Maggioni AP, **Nodari S**, Konstam MA, Butler J, Filippatos G; EVEREST Trial investigators. Haemoconcentration, renal function, and post-discharge outcomes among patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial. *Eur J Heart Fail*. 2013 Dec;15(12):1401-11.
108. Vaduganathan M, Greene SJ, Ambrosy AP, Mentz RJ, Fonarow GC, Zannad F, Maggioni AP, Konstam MA, Subacius HP, **Nodari S**, Butler J, Gheorghiade M; EVEREST Trial Investigators. Relation of serum magnesium levels and postdischarge outcomes in patients

- hospitalized for heart failure (from the EVEREST Trial). *Am J Cardiol.* 2013 Dec 1;112(11):1763-9.
109. Gheorghide M, Vaduganathan M, Greene SJ, Mentz RJ, Adams KF Jr, Anker SD, Arnold M, Baschiera F, Cleland JG, Cotter G, Fonarow GC, Giordano C, Metra M, Misselwitz F, Mühlhofer E, **Nodari S**, Frank Peacock W, Pieske BM, Sabbah HN, Sato N, Shah MR, Stockbridge NL, Teerlink JR, van Veldhuisen DJ, Zalewski A, Zannad F, Butler J. Site selection in global clinical trials in patients hospitalized for heart failure: perceived problems and potential solutions. *Heart Fail Rev.* 2014 Mar;19(2):135-52.
110. Butler J, Fonarow GC, Zile MR, Lam CS, Roessig L, Schelbert EB, Shah SJ, Ahmed A, Bonow RO, Cleland JG, Cody RJ, Chioncel O, Collins SP, Dunmon P, Filippatos G, Lefkowitz MP, Marti CN, McMurray JJ, Misselwitz F, **Nodari S**, O'Connor C, Pfeffer MA, Pieske B, Pitt B, Rosano G, Sabbah HN, Senni M, Solomon SD, Stockbridge N, Teerlink JR, Georgiopoulou VV, Gheorghide M. Developing therapies for heart failure with preserved ejection fraction: current state and future directions. *JACC Heart Fail.* 2014 Apr;2(2):97-112.
111. Ambrosy AP, Fonarow GC, Butler J, Chioncel O, Greene SJ, Vaduganathan M, **Nodari S**, Lam CSP, Sato N, Shah AN, Gheorghide M. The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. *J Am Coll Cardiol.* 2014 Apr 1;63(12):1123-1133. doi: 10.1016/j.jacc.2013.11.053. Epub 2014 Feb 5. PMID: 24491689.
112. Vizzardi E, **Nodari S**, Caretta G, D'Aloia A, Pezzali N, Faden G, Lombardi C, Raddino R, Metra M, Dei Cas L. Effects of spironolactone on long-term mortality and morbidity in patients with heart failure and mild or no symptoms. *Am J Med Sci.* 2014 Apr;347(4):271-6
-
113. Mentz RJ, Greene SJ, Ambrosy AP, Vaduganathan M, Subacius HP, Swedberg K, Maggioni AP, **Nodari S**, Ponikowski P, Anker SD, Butler J, Gheorghide M. Clinical profile and prognostic value of anemia at the time of admission and discharge among patients hospitalized for heart failure with reduced ejection fraction: findings from the EVEREST trial. *Circ Heart Fail.* 2014 May;7(3):401-8. doi: 10.1161/CIRCHEARTFAILURE.113.000840. Epub 2014 Apr 15. PMID: 24737459; PMCID: PMC4151504.
114. Lombardi C, Carubelli V, Lazzarini V, Vizzardi E, Quinzani F, Guidetti F, Rovetta R, **Nodari S**, Gheorghide M, Metra M. Effects of oral amino Acid supplements on functional capacity in patients with chronic heart failure. *Clin Med Insights Cardiol.* 2014 May 21;8:39-44.
115. Mantegazza V, Badagliacca R, **Nodari S**, Parati G, Lombardi C, Di Somma S, Carluccio E, Dini FL, Correale M, Magri D, Agostoni P. Management of heart failure in the new era: the role of scores. *J Cardiovasc Med (Hagerstown).* 2014 Aug 1.
116. Lombardi C, Carubelli V, Lazzarini V, Vizzardi E, Bordonali T, Ciccarese C, Castrini AI, Dei Cas A, **Nodari S**, Metra M. Effects of oral administration of orodispersible levo-carnosine on quality of life and exercise performance in patients with chronic heart failure. *Nutrition.* 2015 Jan;31(1):72-8.

117. Vaduganathan M, Mentz RJ, Greene SJ, Senni M, Sato N, **Nodari S**, Butler J, Gheorghiade M. Combination decongestion therapy in hospitalized heart failure: loop diuretics, mineralocorticoid receptor antagonists and vasopressin antagonists. *Expert Rev Cardiovasc Ther.* 2015;13(7):799-809.
118. Khan SS, Campia U, Chioncel O, Zannad F, Rossignol P, Maggioni AP, Swedberg K, Konstam MA, Senni M, **Nodari S**, Vaduganathan M, Subacius H, Butler J, Gheorghiade M; EVEREST Trial Investigators. Changes in serum potassium levels during hospitalization in patients with worsening heart failure and reduced ejection fraction: from the EVEREST trial. *Am J Cardiol.* 2015 Mar 15; 115(6):790-6.
119. Vaduganathan M, Michel A, Hall K, Mulligan C, **Nodari S**, Shah SJ, Senni M, Triggiani M, Butler J, Gheorghiade M. Spectrum of epidemiological and clinical findings in patients with heart failure with preserved ejection fraction stratified by study design: a systematic review. *Eur J Heart Fail.* 2016 Jan; 18(1):54-65.
120. Greene SJ, Temporelli PL, Campia U, Vaduganathan M, Degli Esposti L, Buda S, Veronesi C, Butler J, **Nodari S**. Effects of Polyunsaturated Fatty Acid Treatment on Postdischarge Outcomes After Acute Myocardial Infarction. *Am J Cardiol.* 2016 Feb 1; 117(3):340-6.
121. Lombardi C, Carubelli V, Rovetta R, Castrini AI, Vizzardi E, Bondei I, Sciatti E, Manerba A, Benlodi E, **Nodari S**, Metra M. Prognostic value of serial measurements of blood urea nitrogen in ambulatory patients with chronic heart failure. *Panminerva Med.* 2016 Mar;58(1):8-15.
122. Vaduganathan M, De Palma G, Manerba A, Goldoni M, Triggiani M, Apostoli P, Dei Cas L, **Nodari S**. Risk of Cardiovascular Hospitalizations from Exposure to Coarse Particulate Matter (PM10) Below the European Union Safety Threshold. *Am J Cardiol.* 2016 Apr 15;117(8):1231-5.
123. Cadeddu C, Mercurio V, Spallarossa P, **Nodari S**, Triggiani M, Monte I, Piras R, Madonna R, Pagliaro P, Tocchetti CG, Mercurio G Preventing antiblastic drug-related cardiomyopathy: old and new therapeutic strategies.. *J Cardiovasc Med (Hagerstown).* 2016 May;17 Suppl 1:S64-75
124. Novo G, Cadeddu C, Sucato V, Pagliaro P, Romano S, Tocchetti CG, Zito C, Longobardo L, **Nodari S**, Penco M Role of biomarkers in monitoring antiblastic cardiotoxicity. *J Cardiovasc Med (Hagerstown).* 2016 May;17 Suppl 1:S27-34.
125. Voors AA, Düngen HD, Senni M, **Nodari S**, Agostoni P, Ponikowski P, Bax JJ, Butler J, Kim RJ, Dorhout B, Dinh W, Gheorghiade M. Safety and Tolerability of Neladenoson Bialanate, a Novel Oral Partial Adenosine A1 Receptor Agonist, in Patients With Chronic Heart Failure. *J Clin Pharmacol.* 2017 Apr;57(4):440-451. doi: 10.1002/jcph.828. Epub 2016 Nov 9. PMID: 27624622.
126. Mattioli AV, Palmiero P, Manfrini O, Puddu PE, **Nodari S**, Dei Cas A, Mercurio G, Scrutinio D, Palermo P, Sciomer S, Di Francesco S, Novo G, Novo S, Pedretti RFE, Zito A, Parati G, Pedrinelli R, Farinetti A, Maiello M, Moscucci F, Tenaglia RL, Sucato V, Triggiani M, Cugusi L, Scicchitano P, Saba PS, Ciccone MM.; Mediterranean diet impact on cardiovascular diseases: a narrative review.; *J Cardiovasc Med (Hagerstown).* 2017 Dec;18(12):925-935. doi: 10.2459/JCM.0000000000000573.

127. Dauriz M, Targher G, Temporelli PL, Lucci D, Gonzini L, Nicolosi GL, Marchioli R, Tognoni G, Latini R, Cosmi F, Tavazzi L, Maggioni AP; Prognostic Impact of Diabetes and Prediabetes on Survival Outcomes in Patients With Chronic Heart Failure: A Post-Hoc Analysis of the GISSI-HF (Gruppo Italiano per lo Studio della Sopravvivenza nella Insufficienza Cardiaca-Heart Failure) Trial. GISSI-HF Investigators. *J Am Heart Assoc.* 2017 Jul 5;(7). pii: e005156. doi: 10.1161/JAHA.116.005156
128. Greene SJ, Butler J, Fonarow GC, Subacius HP, Ambrosy AP, Vaduganathan M, Triggiani M, Solomon SD, Lewis EF, Maggioni AP, Böhm M, Chioncel O, Nodari S, Senni M, Zannad F, Gheorghiade M; ASTRONAUT Investigators and Coordinators.; Pre-discharge and early post-discharge troponin elevation among patients hospitalized for heart failure with reduced ejection fraction: findings from the ASTRONAUT trial.; *Eur J Heart Fail.* 2018 Feb;20(2):281-291. doi: 10.1002/ejhf.1019. Epub 2017 Oct 17.
129. Correale M, Monaco I, Brunetti N, Di Biase M, Metra M, Nodari S, Butler J, Gheorghiade M; On behalf of students of Master Program on Drug Development for Heart Failure; Redefining biomarkers in heart failure; *Heart Failure Reviews*; March 2018, Volume 23, Issue 2, pp 237–253
130. Nodari S, Butler J, Temporelli PL. Questioning the Associations of ω -3 Fatty Acid Supplement Use With Cardiovascular Disease Risks. *JAMA Cardiol.* 2018 Aug 1;3(8):781. doi: 10.1001/jamacardio.2018.1309. PMID: 29874369.
131. Mercurio V, Palazzuoli A, Correale M, Lombardi C, Passantino A, Ravera A, Ruocco G, Sciatti E, Triggiani M, Lagioia R, Scrutinio D, Tocchetti CG, Nodari S. Right heart dysfunction: from pathophysiologic insights to therapeutic options: a translational overview. *J Cardiovasc Med (Hagerstown).* 2018 Nov;19 (11):613-623.
132. Dungen HD, Petroni R, Correale M, Coiro S, Monitillo F, Triggiani M, Leone M, Antohi EL, Ishihara S, Sarwar CMS, Sabbah HN, Memo M, Metra M, Butler J, Nodari S and Gheorghiade M. A new educational program in heart failure drug development: the Brescia international master program. *J Cardiovasc Med (Hagerstown).* 2018 Aug;19 (8):411-421. doi: 10.2459/JCM.0000000000000669.
133. Breccia M, Pregno P, Spallarossa P, Arboscello E, Ciceri F, Giorgi M, Grossi A, Mallardo M, Nodari S, Ottolini S, Sala C, Tortorella G, Rosti G, Pane F, Minotti G, Baccarani M. Identification, prevention and management of cardiovascular risk in chronic myeloid leukaemia patients candidate to ponatinib: an expert opinion. *Annals of Hematology.* 2017 Apr;96(4):549-558. doi: 10.1007/s00277-016-2820-x. Epub 2016 Sep 30.
134. Senni M, Parrella P, De Maria R, Cottini C, Bohm M, Ponikowski P, Filippatos G, Tribouilloy C, Di Lenarda A, Oliva F, Pulignano G, Ciccoira M, Nodari S, Porcu M, Cioffi G, Gabrielli D, Parodi O, Ferrazzi P, Gavazzi A. Predicting heart failure outcome from cardiac and comorbid conditions: the 3C-HF score. *International Journal of Cardiology.* 2013 Feb 20;163(2):206-11. doi: 10.1016/j.ijcard.2011.10.071. Epub 2011 Nov 29.
135. Antonione R, Sinagra G, Moroni M, Correale M, Redaelli D, Scrutinio D, Malinverni E, Nodari S, Calabrò R, Penco I, Mercurio G. Palliative care in the cardiac setting: a consensus

- document of the Italian Society of Cardiology/Italian Society of palliative Care (SIC/SICP). *G Ital Cardiol (Rome)*. 2019 Jan;20(1):46-61. Doi: 10.1714/3079.30720
136. Düngen HD, Kober L, **Nodari S**, Schou M, Otto C, Becka M, Kanefendt F, Winkelmann BR, Gislason G, Richard F, Nielsen OW, Gheorghiadu M, Senni M. Safety and Tolerability of the Chymase Inhibitor Fulacimstat in Patients With Left Ventricular Dysfunction After Myocardial Infarction-Results of the CHIARA MIA 1 Trial. *Clin Pharmacol Drug Dev*. 2019 Oct;8(7):942-951. doi: 10.1002/cpdd.633. Epub 2018 Nov 19. PMID: 30452784.
 137. Maltese PE, Aldanova E, Kriuchkova N, Averianov A, Manara E, Paolacci S, Bruson A, Miotto R, Sartori M, Guerri G, Zuntini M, Marceddu G, Tezzele S, Tadtavaeva K, Chernova A, Aksyutina N, Nikulina S, **Nodari S**, Bertelli M. Putative role of Brugada syndrome genes in familial atrial fibrillation. *Eur Rev Med Pharmacol Sci*. 2019 Sep;23(17):7582-7598. doi: 10.26355/eurev_201909_18880. PMID: 31539150.
 138. Krasi G, Precone V, Paolacci S, Stuppia L, **Nodari S**, Romeo F, Perrone M, Bushati V, Dautaj A, Bertelli M. Genetics and pharmacogenetics in the diagnosis and therapy of cardiovascular diseases. *Acta Biomed*. 2019 Sep 30;90(10-S):7-19. doi: 10.23750/abm.v90i10-S.8748. PMID: 31577248; PMCID: PMC7233637.
 139. Correale M, Paolillo S, Mercurio V, Limongelli G, Barillà F, Ruocco G, Palazzuoli A, Scrutinio D, Lagioia R, Lombardi C, Lupi L, Magri D, Masarone D, Pacileo G, Scicchitano P, Matteo Ciccone M, Parati G, Tocchetti CG, **Nodari S**. Comorbidities in chronic heart failure: An update from Italian Society of Cardiology (SIC) Working Group on Heart Failure. *Eur J Intern Med*. 2020 Jan;71:23-31. doi: 10.1016/j.ejim.2019.10.008. Epub 2019 Nov 8. PMID: 31708358.
 140. Correale M, Paolillo S, Ruocco G, Palazzuoli A, **Nodari S**; from Italian Society of Cardiology (SIC) Working Group on Heart Failure. Comprehensive heart failure assessment: A challenge to modify the course of heart failure. Author's reply. *Eur J Intern Med*. 2020 Apr;74:125-126. doi: 10.1016/j.ejim.2020.01.020. Epub 2020 Feb 9. PMID: 32046942.
 141. Butler J, Khan MS, Anker SD, Fonarow GC, Kim RJ, **Nodari S**, O'Connor CM, Pieske B, Pieske-Kraigher E, Sabbah HN, Senni M, Voors AA, Udelson JE, Carr J, Gheorghiadu M, Filippatos G. Effects of Elamipretide on Left Ventricular Function in Patients With Heart Failure With Reduced Ejection Fraction: The PROGRESS-HF Phase 2 Trial. *J Card Fail*. 2020 May;26(5):429-437. doi: 10.1016/j.cardfail.2020.02.001. Epub 2020 Feb 14. PMID: 32068002.
 142. Antonione R, **Nodari S**, Fieramosca M. Criteri di selezione del malato con scompenso cardiaco da avviare a cure palliative [Selection criteria to palliative care implementation in advanced heart failure]. *G Ital Cardiol (Rome)*. 2020 Apr;21(4):272-277. Italian. doi: 10.1714/3328.32987. PMID: 32202559.
 143. Gorni G, Correale M, **Nodari S**, Sinagra G. Inotropi palliativi nello scompenso cardiaco avanzato: organizzazione e gestione [Palliative inotropic therapy in advanced heart failure: organization and management]. *G Ital Cardiol (Rome)*. 2020 Apr;21(4):296-302. Italian. doi: 10.1714/3328.32990. PMID: 32202562.
 144. Romanò M, Moroni M, Antonione R, Fieramosca M, **Nodari S**, Valle A. Cure palliative e scompenso cardiaco: considerazioni su costo-efficacia e risultati clinici [Palliative care and heart

- failure: some remarks about cost-effectiveness and clinical results]. *G Ital Cardiol (Rome)*. 2020 Apr;21(4):303-305. Italian. doi: 10.1714/3328.32991. PMID: 32202563.
145. Inciardi RM, Adamo M, Lupi L, Cani DS, Di Pasquale M, Tomasoni D, Italia L, Zaccone G, Tedino C, Fabbriatore D, Curnis A, Faggiano P, Gorga E, Lombardi CM, Milesi G, Vizzardi E, Volpini M, **Nodari S**, Specchia C, Maroldi R, Bezzi M, Metra M. Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy. *Eur Heart J*. 2020 May 14;41(19):1821-1829. doi: 10.1093/eurheartj/ehaa388. PMID: 32383763; PMCID: PMC7239204.
146. De Rosa S, Spaccarotella C, Basso C, Calabrò MP, Curcio A, Filardi PP, Mancone M, Mercurio G, Muscoli S, **Nodari S**, Pedrinelli R, Sinagra G, Indolfi C; Società Italiana di Cardiologia and the CCU Academy investigators group. Reduction of hospitalizations for myocardial infarction in Italy in the COVID-19 era. *Eur Heart J*. 2020 Jun 7;41(22):2083-2088. doi: 10.1093/eurheartj/ehaa409. PMID: 32412631; PMCID: PMC7239145
147. Antonione R, Fieramosca M, Moroni M, **Nodari S**, Valle A. Inquadramento e gestione dei sintomi nel cardiopatico candidato a cure palliative [Overview and symptom management in heart failure patients eligible for palliative care]. *G Ital Cardiol (Rome)*. 2020 Aug;21(8):629-638. Italian. doi: 10.1714/3405.33897. PMID: 32686790.
148. Calcaterra G, Bassareo PP, **Nodari S**, Barilla' F, Di Franco A, Romeo F. An expression of concern on research during the Covid-19 pandemic. *J Cardiovasc Med (Hagerstown)*. 2020 Oct;21(10):838-839. doi: 10.2459/JCM.0000000000001074. PMID: 32740445.
149. Kiani AK, Amato B, Maitz S, **Nodari S**, Benedetti S, Agostini F, Lorusso L, Capelli E, Dautaj A, Bertelli M. Genetic test for Mendelian fatigue and muscle weakness syndromes. *Acta Biomed*. 2020 Nov 9;91(13-S): e2020001. doi: 10.23750/abm.v91i13-S.10642. PMID: 33170160.
-
150. Molinari G, Brunetti ND, **Nodari S**, Molinari M, Spagna G, Ioakim M, Migliore G, Dattoli V, Di Cillo O. Impact of 2020 SARS-CoV-2 outbreak on telemedicine management of cardiovascular disease in Italy. *Intern Emerg Med*. 2021 Aug;16(5):1191-1196. doi: 10.1007/s11739-020-02564-0. Epub 2020 Dec 8. PMID: 33294959; PMCID: PMC7722980.
151. Strangio A, Leo I, Spaccarotella CAM, Barillà F, Basso C, Calabrò MP, Curcio A, Filardi PP, Mancone M, Mercurio G, Muscoli S, **Nodari S**, Pedrinelli R, Romeo F, Sinagra G, Indolfi C. Effects of the COVID-19 pandemic on the formation of fellows in training in cardiology. *J Cardiovasc Med (Hagerstown)*. 2021 Sep 1;22(9):711-715. doi: 10.2459/JCM.0000000000001185. PMID: 34009835.
152. Indolfi C, Barillà F, Basso C, Ciccone MM, Curcio A, Mancone M, Mercurio G, Muscoli S, **Nodari S**, Pedrinelli R, Romeo F, Sinagra G, Filardi PP. *G Ital Cardiol (Rome)*. Position paper of the Italian Society of Cardiology (SIC) on COVID-19 vaccine priority in patients with cardiovascular diseases 2021 May;22(5):363-375. doi: 10.1714/3592.35745. PMID: 33960979 Italian. PMID:33960979 Italian.
153. Correale M, Tricarico L, Fortunato M, Mazzeo P, **Nodari S**, Di Biase M, Brunetti ND. New Targets in Heart Failure Drug Therapy. *Front Cardiovasc Med*. 2021 May 5;8:665797. doi: 10.3389/fcvm.2021.665797. PMID: 34026873; PMCID: PMC8131549.

154. Indolfi C, Barillà F, Basso C, Ciccone MM, Curcio A, Mancone M, Mercurio G, Muscoli S, **Nodari S**, Pedrinelli R, Romeo F, Sinagra G, Filardi PP. Risposta a "Stabilire le priorità, il caso del vaccino COVID-19" [Reply to "Defining priorities, the case of of COVID-19 vaccine"]. *G Ital Cardiol (Rome)*. 2021 Jun;22(6):510-511. Italian. doi: 10.1714/3612.35937. PMID: 34037598.
155. Sinagra G, Porcari A, Merlo M, Barillà F, Basso C, Ciccone MM, Curcio A, Mancone M, Mercurio G, Muscoli S, **Nodari S**, Pedrinelli R, Spaccarotella C, Filardi PP, Indolfi C. Myocarditis and pericarditis following mRNA COVID-19 vaccination. Expert opinion of the Italian Society of Cardiology. *G Ital Cardiol (Rome)*. 2021 Nov;22(11):894-899. Doi: 10.1714/3689.36747. PMID: 34709228 Italian.
156. Paolillo S, Ruocco G, Filardi PP, Palazzuoli A, Tocchetti CG, **Nodari S**, Lombardi C, Metra M, Correale M; "Right and Left Heart Failure Study Group" of the Italian Society of Cardiology. Direct oral anticoagulants across the heart failure spectrum: the precision medicine era. *Heart Fail Rev*. 2022 Jan;27(1):135-145. doi: 10.1007/s10741-020-09994-0. PMID: 32583229.
157. **Nodari S**, Fioretti F, Barilla F. Redefining diabetes mellitus treatments according to different mechanisms beyond hypoglycaemic effect. *Heart Fail Rev*. 2022 Feb 8:1–19. doi: 10.1007/s10741-021-10203-9. Epub ahead of print. PMID: 35133551; PMCID: PMC8821791.
158. Carluccio E, Dini FL, Bitto R, Ciccarelli M, Correale M, D'Agostino A, Dattilo G, Ferretti M, Grelli A, Guida S, Jacoangeli F, Lupi L, Luschi L, Masarone D, Mercurio V, Pacileo G, Pugliese NR, Rispoli A, Scelsi L, Tocchetti CG, Brunetti ND, Palazzuoli A, Piepoli M, **Nodari S**, Ambrosio G; Working Group on Heart Failure of the Italian Society of Cardiology. Benefit from sacubitril/valsartan is associated with hemodynamic improvement in heart failure with reduced ejection fraction: An echocardiographic study. *Int J Cardiol*. 2022 Mar 1;350:62-68. doi: 10.1016/j.ijcard.2022.01.004. Epub 2022 Jan 5. PMID: 34998946.
159. Filardi PP, Paolillo S, Indolfi C, Agostoni P, Basso C, Barillà F, Correale M, Curcio A, Mancone M, Merlo M, Metra M, Muscoli S, **Nodari S**, Palazzuoli A, Pedrinelli R, Pontremoli R, Senni M, Volpe M, Sinagra G. Position paper della Società Italiana di Cardiologia: Il blocco del sistema renina-angiotensina-aldosterone (RAAS) nel paziente con scompenso cardiaco – Parte I: Dalla scoperta del RAAS ai trial clinici [Position paper of the Italian Society of Cardiology: The renin-angiotensin-aldosterone system (RAAS) blockade in heart failure patients - Part I: From RAAS identification to clinical trials]. *G Ital Cardiol (Rome)*. 2022 Mar;23(3):217-228. Italian. doi: 10.1714/3751.37342. PMID: 35343504.
160. Perrone-Filardi P, Paolillo S, Agostoni P, Basile C, Basso C, Barillà F, Correale M, Curcio A, Mancone M, Merlo M, Metra M, Muscoli S, **Nodari S**, Palazzuoli A, Pedrinelli R, Pontremoli R, Senni M, Volpe M, Indolfi C, Sinagra G. Renin-angiotensin-aldosterone system inhibition in patients affected by heart failure: efficacy, mechanistic effects and practical use of sacubitril/valsartan. Position Paper of the Italian Society of Cardiology. *Eur J Intern Med*. 2022 Apr 22:S0953-6205(22)00142-X. doi: 10.1016/j.ejim.2022.04.006. Epub ahead of print. PMID: 35469709.
161. Sinagra G, Porcari A, Merlo M, Fabris E, Imazio M, Barillà F, Basso C, Ciccone MM, Curcio A, Mancone M, Mercurio G, Muscoli S, **Nodari S**, Pedrinelli R, Spaccarotella C, Filardi PP, Indolfi C. Update 2022 dell'Expert Opinion della Società Italiana di Cardiologia su miocarditi, pericarditi e vaccini contro il COVID-19 [2022 Update on myocarditis and pericarditis following

- COVID-19 vaccination. Expert Opinion of the Italian Society of Cardiology]. *G Ital Cardiol (Rome)*. 2022 Jun;23(6):408-413. Italian. doi: 10.1714/3810.37934. PMID: 35674028.
162. Correale M, Petroni R, Coiro S, Antohi EL, Monitillo F, Leone M, Triggiani M, Ishihara S, Dungen HD, Sarwar CMS, Memo M, Sabbah HN, Metra M, Butler J, Nodari S. Paradigm shift in heart failure treatment: are cardiologists ready to use gliflozins? *Heart Fail Rev*. 2022 Jul;27(4):1147-1163. doi: 10.1007/s10741-021-10107-8. Epub 2021 Jun 7. PMID: 34097173.
163. Indolfi C, Barillà F, Basso C, Ciccone MM, Curcio A, Gargiulo P, Nodari S, Mercurio G, Mancone M, Muscoli S, Pedrinelli R, Porcari A, Spaccarotella C, Romeo F, Sinagra G, Filardi PP. Expert consensus document della Società Italiana di Cardiologia (SIC): Sequele cardiovascolari post-acute dell'infezione da SARS-CoV-2 [Italian Society of Cardiology (SIC) Expert consensus document: Post-acute cardiovascular sequelae of SARS-CoV-2 infection]. *G Ital Cardiol (Rome)*. 2022 Jul;23(7):491-503. Italian. doi: 10.1714/3831.38166. PMID: 35771014.

Software, world wide web-based publications, exhibits, audiovisual or other teaching material

- 1997 - realization of a multimedia, interactive and simulation program of case reports for teaching the correct clinical, diagnostic and therapeutic approach in patients with cardiovascular disease in collaboration with the Electronic Engineering Department of Politecnico University of Milan.
- 2000 - realization of a multimedia teaching software regarding the chronic heart failure in collaboration with the Heart Failure Group Study of the Italian Society of Cardiology.
- 2001 - participation at the DEDALO project in the realization of a Cd-Rom and a booklet entitled Epidemiology of the depression in cardiovascular disease.
- 2008 – Participation in the realization of an E-Book of cardiovascular medicine for medical students edited by Italian Society of Cardiology. www.cse.it/ebook/ebook/default3.asp
- 2021- realization of the Master Book edited by “Istituto Policletto”

PRESENTATIONS AND INVITED LECTURES

More than 450 presentations at national and international congress.

- *I nitrati nella terapia cardiovascolare.* X Corso di Aggiornamento in Cardiologia, Bormio 2-5 Aprile 2002
- *La terapia medica dell'insufficienza cardiaca sintomatica.* XI Corso di Aggiornamento in Cardiologia, Bormio 8-11 Aprile 2003
- *Diabete ed insufficienza cardiaca: esistono peculiarità terapeutiche?* XIII Corso di aggiornamento "Attualità in tema di Rischio Cardiovascolare ed Insufficienza Cardiaca: come valutarli, come trattarli". Bormio 12-15 Aprile 2005
- *L'obesità: fattore o cofattore di rischio?* XIV Corso di Aggiornamento in Cardiologia, Bormio 4-8 Aprile 2006
- *I nitrati: ancora attuali e in quali patologie?* XIV Corso di Aggiornamento in Cardiologia, Bormio 4-8 Aprile 2006
- *Sistema delle endorfine e prevenzione cardiovascolare: un reale progresso?* XV Corso di Aggiornamento in Cardiologia, Bormio 17-21 Aprile 2007
- *La prevenzione degli eventi ischemici nella pratica clinica: il ruolo degli antagonisti neuroumorali.* XV Corso di Aggiornamento in Cardiologia, Bormio 17-21 Aprile 2007
- *Endotelio, nitrati e patologia cardiovascolare.* XVI Corso di Aggiornamento in Cardiologia, Bormio 1-4 Aprile 2008
- *Funzione endoteliale, recettori beta-3 adrenergici e scompenso cardiaco: il ruolo dei nuovi beta-bloccanti.* XVI Corso di Aggiornamento in Cardiologia, Bormio 1-4 Aprile 2008
- *Significato dell'apporto di n-3 PUFA nelle malattie cardiovascolari.* XVIII Corso di Aggiornamento in Cardiologia, Bormio 13-16 Aprile 2010
- *Gli n-3 PUFA nella patologia cardiovascolare.* XIX Corso di Aggiornamento in Cardiologia, Bormio 19-22 Aprile 2011
- *Indicazione agli esami radiologici (TAC, TAC Coronarica, RMN).* Corso di Aggiornamento: Nuovi Protocolli Per La Gestione Del Paziente Con Scompenso Cardiaco. Brescia, 1 Dicembre 2011
- *La terapia del paziente cronico.* 72° Congresso Nazionale SIC. 10-12 Dicembre 2011.
- *Diagnosi precoce di disfunzione ventricolare sinistra: metodologia e impatto clinico.* 72° Congresso Nazionale SIC. 10-12 Dicembre 2011.

- *Epidemiologia, forme cliniche ed impatto economico dello SC*. Corso per Formatori Prevenzione dello Scompenso Cardiaco e delle Sue Recidive. Alghero 19-21 Dicembre 2011
 - Lettura *L'evoluzione delle conoscenze nell'insufficienza cardiaca*. Corso per Formatori Prevenzione dello Scompenso Cardiaco e delle Sue Recidive. Alghero 19-21 Dicembre 2011
 - *Novità nella terapia antiaggregante delle sindromi coronariche acute*. XX Corso di Aggiornamento in Cardiologia, Bormio 17-20 Aprile 2012
 - *Gli n-3 PUFA oggi*. XX Corso di Aggiornamento in Cardiologia, Bormio 17-20 Aprile 2012
 - Poster Presentation: *Predictors of outcome in chronic heart failure outpatients*. ESC - HF Belgrado 18-22 Maggio 2012.
 - *Ipertensione e scompenso cardiaco*. IPERSPE 2012, Roma 22-23 Maggio 2012
 - *I beta bloccanti nel trattamento dello scompenso cardiaco*. IPERSPE 2012, Roma 22-23 Maggio 2012
 - *Ruolo dei PUFA n-3 e prevenzione cardiovascolare: a chi, come e perchè*. Dislipidemie e comorbidità: come allargare l'orizzonte della prevenzione. Bologna 15-16 Giugno 2012
 - Poster Presentation: *Low relative lymphocyte count predicts adverse post-discharge outcomes in patients hospitalized for worsening heart failure: insights from the EVEREST trial*. ESC Munich 25-29 Agosto 2012.
-
- *Ipertensione, danno d'organo, scompenso. Dalla cura della patologia alla cura del paziente*. Ipertensione e HDL: quali fattori di rischio di malattia cardiovascolare. Brescia 29 Settembre 2012
 - Lecture: *Ivabradina e scompenso cardiaco*. Congresso Regionale FADOI - ANIMO Calabria, La centralità del paziente in medicazione interna. Vibo Valentia 12-13 Ottobre 2012.
 - *Ipertensione e scompenso cardiaco*. Ipertensione e patologia cardiaca: dalla ricerca alla clinica, Napoli 16-17 Ottobre 2012.
 - *I beta bloccanti nel trattamento dello scompenso cardiaco*. Ipertensione e patologia cardiaca: dalla ricerca alla clinica, Napoli 16-17 Ottobre 2012.
 - *I markers biochimici*. XIV Congresso - Insufficienza Cardiaca: Nuove prospettive di Trattamento. Brescia 18-19 Ottobre 2012.
 - *n-3 PUFA: dalla prevenzione al trattamento*. XIV Congresso - Insufficienza Cardiaca: Nuove prospettive di Trattamento. Brescia 18-19 Ottobre 2012.
-
- *Biomarker per l'identificazione precoce della disfunzione ventricolare nel paziente oncologico*. 73°

Congresso Nazionale SIC. Roma, 14-17 Dicembre 2012

- *Fibrillazione atriale e insufficienza cardiaca.* 73° Congresso Nazionale SIC. Roma, 14-17 Dicembre 2012
- *Ipertensione, danno d'organo, scompenso. Dalla cura della patologia alla cura del paziente.* Ipertensione e HDL: quali fattori di rischio di malattia cardiovascolare, Brescia 17 Gennaio 2013.
- *Scompenso e BPCO.* VI Convegno Regionale SICOA Lombardia. Malattie Cardiovascolari e Condizioni Associate. Brescia, 26 Gennaio 2013
- *I PUFA n-3 nella cardiopatia ischemica.* III Incontro Ecm: La terapia cardiovascolare si adatta ai tempi. Salò 2 Marzo 2013.
- *n-3 PUFA, dalla prevenzione cardiovascolare al trattamento dell'insufficienza cardiaca.* XX Corso di Aggiornamento in Cardiologia, Bormio 9-12 Aprile 2013
- *Novità nella terapia antiaggregante delle sindromi coronariche acute.* XX Corso di Aggiornamento in Cardiologia, Bormio 9-12 Aprile 2013
- *La terapia dell'insufficienza cardiaca: cosa c'è di nuovo.* XX Corso di Aggiornamento in Cardiologia, Bormio 9-12 Aprile 2013
- *PUFA n-3, oltre la cardiopatia ischemica: cosa ci dicono i più recenti trial clinici?* 4th Update on Dyslipidemia – Dislipidemie e Comorbidità: come allargare l'orizzonte della prevenzione. Milano 9-10 Maggio 2013
- *Fibrillazione atriale ed insufficienza cardiaca.* XII Congresso Nazionale I.C.I.S.C.U. Imaging cardiovascolare: integrazione tra diagnosi e decision making clinico terapeutico. Brindisi 22-24 Maggio 2013.
- *BPCO e insufficienza cardiaca.* XIII Scilla Cuore, Scilla 23-26 Maggio 2013.
- *Changes in serum potassium concentration in hospitalized heart failure patients.* Heart failure 2013. Lisbon (Portugal) 25-28 Maggio 2013
- *AHF Patient Journey.* Multidisciplinary approach to the Acute Heart Failure management. Brescia 26-27 Settembre 2013
- *n-3 PUFA dalla prevenzione alla terapia cardiovascolare.* Prevenzione Cardiovascolare, Nutraceutica e Nutrizione. Brescia 28 Settembre 2013.
- *Lecture: Aminoacidi e scompenso cardiaco.* III Corso di Aggiornamento SICOA. L'esperienza del medico sul territorio, vera linea guida della gestione e cura del paziente. Monguzzo (CO), 5 Ottobre 2013.

- *Il cuore insufficiente nei generi: differenti fenotipi?* 3° Congresso Nazionale sulla Medicina di Genere. Padova 10-11 Ottobre 2013
- Poster: *Particulate matter air pollutants and acute cardiovascular hospitalization*. Acute Cardiac Care 2013. Madrid, 12-14 Ottobre 2013
- *Acidi grassi Omega-3 e le evidenze scientifiche nello scompenso cardiaco*. Progetto A.A.A. Alliance Against Atherosclerosis. Bologna 18-19 Ottobre 2013
- *Scompenso Cardiaco nella donna con Diabete*. Panorama Diabete – Forum Nazionale di Operatori e Professioni. Riccione 22 Ottobre 2013
- *Omega-3 fatty acids in cardiovascular prevention: how and when?* 36° Congresso Nazionale della Società Italiana di Farmacologia. Torino 23-26 Ottobre 2013
- *Prevenzione e trattamento del tromboembolismo venoso*. Convegno Novità in tema di terapia anticoagulante orale. Rezzato (BS), 9 Novembre 2013
- *Scompenso cardiaco cronico e rene*. V Congresso Nazionale Società Italiana di Nefrocardiologia. Trani (BT), 14-16 Novembre 2013
- *Il beta bloccante nel paziente con scompenso cardiaco BPCO*. V Convegno Il management dell'acqua e del sodio: quale ruolo nello scompenso cardiaco. Palermo 15-16 Novembre 2013.
- *Utilizzo clinico dei profili polimorfici in cardiologia*. Cardiogenetica e cardiogenomica: le novità. Varese, 9 Dicembre 2013
- *L'attivazione neuroormonale e infiammatoria*. 74° Congresso Nazionale SIC. Roma 14-16 dicembre 2013
- *Particolato sottile, morbilità e mortalità cardiovascolare*. 74° Congresso Nazionale SIC. Roma 14-16 dicembre 2013
- *Epidemiologia della fibrillazione atriale*. Fibrillazione atriale, ictus e nuove strategie terapeutiche. 19 Dicembre 2013
- *Heart Failure*. 6th International Cardio Event – Cardiology Towards the Future: “Choosing Wisely” to innovate. Florence, February 6-8 2014
- *Il ruolo degli antialdosteronici: nuove prospettive*. I progressi della terapia cardiovascolare. Salò, 1 Marzo 2014
- *I nuovi anticoagulanti orali nella prevenzione del rischio trombo-embolico: dati clinici*. Congresso Nazionale Nuove Prospettive In Cardiologia. Cremona, 28-29 Marzo 2014

- Poster Presentation: *The possible role of genetic variants in predicting antracycline-induced cardiotoxicity*. ACC.14 - 63rd Annual Scientific Session & Expo. Washington DC, USA, 29-30 Marzo 2014
- *n-3 PUFA nella prevenzione e trattamento delle malattie cardiovascolari. Tra prescrivibilità e nuove linee guida*. XXI Corso di Aggiornamento in Cardiologia, Bormio 8-11 Aprile 2014
- *Il trattamento precoce con antiaggreganti orali in pazienti con SCA: nuove evidenze*. XXI Corso di Aggiornamento in Cardiologia, Bormio 8-11 Aprile 2014
- *Inquinamento ambientale e rischio cardiovascolare*. XXI Corso di Aggiornamento in Cardiologia, Bormio 8-11 Aprile 2014
- *Pharmacogenomics and cardiovascular disease*. 48th Annual Scientific Meeting of the European Society for Clinical Investigation. Utrecht, the Netherlands 30 Aprile – 3 Maggio 2014
- *Iperensione arteriosa e scompenso cardiaco*. Congresso Regionale ARCA Lombardia: La cardiologia si adatta ai tempi. Gardone Riviera, 10 Maggio 2014
- Poster Presentation: *Usefulness of cardiac biomarkers monitoring and echocardiographic evaluation in detecting early myocardial function changes after antracycline treatment*. ESC-HF Atene 17-20 Maggio 2014
- *Il management del paziente scompensato in Lombardia*. 13° Congresso Nazionale ICISCU. Brindisi 22-24 Maggio 2014
- *Novità della terapia dello scompenso cardiaco*. XIV Congresso Scilla Cuore. Scilla, 22-25 Maggio 2014.
- *L'epidemia dello scompenso cardiaco: terapia e implicazioni per il futuro*. Il Cuore In Sardegna IV edizione. Alghero, 3-4 Ottobre 2014
- *Dalla prevenzione primaria alla terapia riabilitativa*. XII Congresso della Società Italiana di Cardiologia Riabilitativa e Preventiva (GICR-IACPR). Genova 23-25 Ottobre 2014
- *Epidemiologia della fibrillazione atriale*. Corso di Aggiornamento: Fibrillazione atriale, ictus e nuove strategie terapeutiche. Brescia, 18 Dicembre 2014
- *Cardiotossicità: strategie di monitoraggio e follow up dei trattamenti antineoplastici*. XXIII Corso di Aggiornamento in Cardiologia. Bormio 14-17 Aprile 2015
- *Management del paziente scompensato*. 14° Congresso Nazionale I.C.I.S.C.U. 14-15 Maggio 2015
- *Il follow up della fibrillazione atriale peri e post operatoria*. Scilla Cuore XV Edizione, 21-24 Maggio 2015.

- Poster Presentation: *Serial cardiac biomarker and echocardiographic evaluation for the early detection of antracycline + trastuzumab cardiotoxicity*. ESC Siviglia. 23-26 Maggio 2015
- *Il trattamento e la gestione dello scompenso cardiaco nel territorio, cosa cambia?* XV Giornate Adriatiche della Cardiologia. Giulianova, 29-30 Maggio 2015.
- Poster Presentation: *Baseline predictive models to identify high-risk patients for cardiotoxicity development: the possible role of genetic polymorphisms*. ESC Congress. London, 29 August-2 September 2015.
- Poster Presentation: *Ritmo project (real time continuous web monitoring) a model of a multidisciplinary approach for safely managing of new therapies*. ESC Congress. London, 29 August-2 September 2015.
- *Scompenso cardiaco con frazione d'iezione conservata: come diagnosticarlo?* I Congresso Apulia Heart Failure 2015. Bari, 1-3 Ottobre 2015
- *Il paziente oncologico*. 76° Congresso Nazionale. Roma, 11-14 Dicembre 2015
- *Diabete e scompenso cardiaco*. 76 Congresso Nazionale. Roma, 11-14 Dicembre 2015
- Tutor: *Simulazione Interattiva – 1° caso clinico didattico*. Progetto “S.Te.P.P.” Support ThErapy Ponatinib Patien. Padova, 19 Gennaio 2016
- *Cancer and cancer therapy*. International Symposium on Innovation in cardiology: still a wishful thinking? Brescia 28-30 Gennaio 2016
- Relatore: *Management del paziente in terapia con ponatinib: focus sul management CV*. Progetto “S.Te.P.P.” Support ThErapy Ponatinib Patient. Milano, 2 Febbraio 2016
- *Il punto di vista dello specialista*. Corso di Aggiornamento Prevenzione Primaria Quando...come...e perchè? Brescia, 25 Febbraio 2016
- *Recenti indicazioni all'impiego dei nuovi anticoagulanti orali*. Aggiornamenti in Tema di Terapia Cardiovascolare. Salò, 27 Febbraio 2016
- *Cardiotossicità acuta e tardiva. Come prevenirle?* Progetto FENICE Future For Clinical Patienta And Clinical Experience. Carcinoma Mammario Triplo Negativo – Approccio multidisciplinare. Brescia, 15 Marzo 2016
- *Lo scompenso: terapia e follow up*. Focus Su Cardiologia e Cardiochirurgia. Brescia, 9 Aprile 2016
- *Scompenso cardiaco acuto: quali farmaci per quali pazienti*. XXIV Corso di Aggiornamento in Cardiologia, Bormio 13-15 Aprile 2016.

- *Aria inquinata e ambiente malato: subire o difendersi?* Brescia, 14 Aprile 2016.
- *TKIs, cuore e vasi.* Corso Residenziale CML Academy 2016. Bologna, 18-19 Aprile 2016
- *Management of cardiac: adverse event.* CML Congress: Choice means life. Roma 29-30 Aprile 2016
- *Multidisciplinary patient case discussion.* CML Congress: Choice means life. Roma 29-30 Aprile 2016
- *Ventricular reshaping approaches for heart failure: state of the art in 2016.* New developments and controversial issues in heart failure. Heart Failure 2016. Florence, May 21-24 2016
- *Mitochondrial function.* Old and new therapeutic targets. Heart Failure 2016. Florence, May 21-24 2016
- Rapid Fire S – Comorbidities. Heart Failure 2016. Florence, May 21-24 2016
- *Cardiomiopatie* (videoconferenza). HEART QUAKE – Powerful vibrations to improve Heart Failure management. Roma, 27 Maggio 2016
- *Principi generali della terapia di associazione.* I target clinici e la “forza” delle associazioni terapeutiche – Farmacologia, clinica ed implicazioni medico-legali nella gestione dell'ipertensione arteriosa e dell'ipercolesterolemia. Venezia, 1- 3 Luglio 2016
- *Strategie cliniche di intervento: linee guida e note AIFA.* I target clinici e la “forza” delle associazioni terapeutiche – Farmacologia, clinica ed implicazioni medico-legali nella gestione dell'ipertensione arteriosa e dell'ipercolesterolemia. Venezia, 1- 3 Luglio 2016
- ESC Congress 2016. Rome, 27-31 August 2016.
- *High Sensitive Cardiac Troponin Plasma Level and Outcom.* Master in Heart Failure – Drug Development at the Crossroad. Brescia, 1-2 September 2016
- *Mitochondria in Heart Failure: an essential target.* Master in Heart Failure – Drug Development at the Crossroad. Brescia, 1-2 September 2016
- *Novità terapeutiche in tema di scompenso cardiaco.* Scilla Cuore XVI Edizione. Reggio Calabria, 22-25 Settembre 2016.
- *Le differenze di genere nella malattia, nel soccorso, nella cura e nella farmacovigilanza.* Laboratorio Interdisciplinare per la Conoscenza – Il benessere di genere: le buone pratiche in medicina. Brescia, 30 Settembre 2016.
- *Sicurezza e maneggevolezza dei NOAC.* Congresso nazionale: Nuove prospettive in cardiologia. Cremona, 7-8 Ottobre 2016.

- *Dai Fattori di rischio allo Scompenso Cardiaco: ruolo dell'ipertensione arteriosa e delle comorbidità.* Dall'ipertensione all'insufficienza cardiaca: aspetti fisiopatologici SIMPOSIO: Strumenti clinici, laboratoristici e strumentali per l'identificazione precoce del danno d'organo cardiaco da ipertensione. Le comorbidità nello Scompenso cardiaco: aspetti epidemiologici e prognostici. SIMPOSIO: BPCO e Scompenso Cardiaco. Brescia, 26 novembre 2016
 - *Il continuum cardiovascolare: lo scompenso cardiaco e la nuova classe di farmaci ARNI.* Ipertensione, dislipidemia e diabete. La triade perfetta. Brescia 11 marzo 2017
 - *La fibrillazione atriale, un argomento sempre dibattuto. Flecainide a lento rilascio: una nuova opportunità di terapi aper la fibrillazione atriale. Caso clinico: flecainide a lento rilascio.* Quali novità farmacologiche in campo cardiovascolare per il controllo ottimale del paziente e per una vera aderenza. Brescia, 8 aprile 2017
 - *Ottimizzazione del trattamento farmacologico.* La gestione moderna dello scompenso cardiaco. Roma 5-6 maggio 2017
 - *Inquinamento atmosferico e cardiopatia ischemica.* Focus su cardiologia e cardiocirurgia IV edizione. Brescia, 20 maggio 2017
 - *Principi generali della terapia di associazione. Strategie cliniche di intervento nell'ipercolesterolemia: nuove linee guida e nota AIFA.* Presente e futuro delle associazioni terapeutiche nella orevenziuone delle malattie cardiovascolari. Venezia, 30giugno-2 luglio 2017
 - *Scompenso cardiaco con frazione d'iezione compromessa: oltre la modulazione neuro-ormonale.* Apulia Heart Failure. Bari 5-6 ottobre 2017
-
- *Razionale, vantaggi e limiti degli inibitori della proteina PCSK9.* Convegno SICOA. Gardone Riviera, 7 ottobre 2017
 - *Omega 3 e ipertrigliceridemia. Omega 3 nel paziente coronaropatico.* Progetto Farmalabs. Firenze, 21 ottobre 2017
 - *Prevenzione delle malattie cardiovascolari in perimenopausa.* Il cuore della donna. Brescia 24 ottobre 2017
 - *Ipertensione, Ivabradina e cardi tossicità (moderazione). Terapia con NOAC: dai trail clinici al mondo reale. Nuovi target terapeutici nell'insufficienza cardiaca.* I tempi del cuore. Palermo, 27-29 ottobre 2017
 - *Approccio fisiopatologico al trattamento dello SC acuto: quando utilizzare diuretici, inotropi, vasodilatatori? Omega 3 nello scompenso: quale ruolo nella prevenzione della FA e nel miglioramento della funzione contrattile.* PLACE 2017. Roma, 22-24 novembre 2017
 - *Le complicanze cardiovascolari con gli inibitori delle tirosin-chinasi.* Il paziente ematologico complicato. Brescia, 1 dicembre 2017

- *Piano assistenziale individuale e patto di cura. Gestione dei malati cronici: la presa in Carico. Prospettive ed implicazioni dell'ASST Spedali Civili. Brescia, 23 novembre 2017-6 dicembre 2017*
- *I biomarcatori nella pratica clinica: quanto hanno contribuito a modificare il trattamento e l'outcome? 78° Congresso Nazionale SIC. Roma, 15-18 dicembre 2017*
- *Nuove frontiere per il trattamento delle dislipidemie. Aggiornamenti in tema di terapia cardiovascolare. Salò 03 marzo 2018*
- *La farmacologia di genere. Brescia, 24 marzo 2018*
- *La farmacologia di genere. Brescia, 24 marzo 2018. Meeting Investigator. Roma, 9-10 aprile 2018. XXVI corso di aggiornamento in cardiologia. Bormio, 10-12 aprile 2018*
- *Esperienze a confronto 2018: Updates and best practice in hf. Roma, 13-14 aprile*
- *Dall'ipertensione arteriosa allo scompenso cardiaco con l'incomodo della fibrillazione atriale. Un percorso eludibile. Convegno E.C.M.. Brescia, 14 aprile 2018*
- *How Telemedicine might impact on congestive heart failure patients. EuroPrevent 2018. Ljubljana, 19-20-21 aprile 2018*
- *Trattamento dello scompenso cardiaco oggi: tra ricerca e innovazione. Brescia, 10 giugno 2018*
- *Dopo lo studio SPRINT quali i target pressori? Aderenza e appropriatezza in tema di terapia cardiovascolare - management clinico e farmacoeconomia. Verona, 14-15 giugno 2018*
- *International meeting on hearth failure: from metabolic disorders to cardiovascular dysfunction. Siena, 28-29 giugno 2018*
- *Antialdosteronici: retaggi del passato e reali prospettive. Venezia, 29 giugno-1 luglio 2018*
- *Il trattamento del tromboembolismo venoso nel paziente oncologico: nuove evidenze. Brescia, 18 luglio 2018*
- *Cardiotossicità da trattamento con TKI nella leucemia mieloide cronica. I tempi del Cuore V edizione. Trieste, 7-9 settembre 2018*
- *La donna e la coppia dopo l'età fertile. II° congresso nazionale verso la medicina genere specifica. Milano, 19-20 settembre 2018*
- *Squilibri elettrolitici. Dai fattori di rischio allo sviluppo di scompenso cardiaco: strategie di prevenzione e trattamento. Matera, 20-22 settembre 2018*

- *L'iter diagnostico nell'ipertrofia cardiaca: l'esperienza della cardiologia day hospital/day service/MAC.* Cardiomiopatie su base genetica. Brescia, 28 settembre 2018
 - *Ruolo dei betabloccanti nel trattamento dello scompenso cardiaco dell'anziano. Implicazioni cliniche dello studio SENIOR.* Convegno ANCE. Palermo, 27-29 settembre 2018
 - *L'insufficienza cardiaca nel soggetto anziano.* Il cuore in... Sardegna. Alghero, 12 ottobre 2018
 - *Lipidi/angina. Due malattie ben conosciute ma con molti lati ancora oscuri.* Grey zones. Bergamo, 12-13 ottobre 2018
 - *Heart Failure and Chronic Obstructive Pulmonary Pathology. Cardiology Case Presentation.* International Panadriatic Meeting on Medical Sciences. Budvs, Montenegro, 19-20 ottobre 2018
 - *Terapia non farmacologica dell'insufficienza cardiaca. Ultrafiltrazione: quando e perché.* 79° Congresso Nazionale SIC- Roma, 14-17 dicembre 2018
 - *XXVII CORSO DI AGGIORNAMENTO IN CARDIOLOGIA per le Scuole dell'Alta Valtellina e per la cittadinanza. Prevenzione primaria e secondaria della cardiopatia ischemica.* Presentazione lettura "Sedentarietà e rischio cardiovascolare". Bormio 12/13 aprile 2019
 - *CONVEGNO ANCE Temi emergenti nella cardiologia del territorio. XIX Edizione "Le gliflozine nel trattamento dello scompenso cardiaco cronico del paziente diabetico".* Palermo 19-21 settembre 2019
-
- *CARDIOBAT 2019 "La terapia antitrombotica nell'anziano"* Trani, 18-19 ottobre 2019
 - *DAI FATTORI DI RISCHIO ALLO SVILUPPO DI SCOMPENSO CARDIACO: STRATEGIE DI PREVENZIONE E TRATTAMENTO.* "Squilibri elettrolitici e prognosi Sorrento" 24 -26 ottobre 2019
 - *Brescia Cuore - Il ruolo dei n-3 PUFA* Brescia, 7-9 novembre 2019
 - *8^ edizione di PLACE 2019 "Ma gli omega 3 hanno un'azione antiaritmica e prevengono la morte improvvisa?"* Roma 22-23 novembre 2019
 - *80° Congresso Nazionale SIC.* Roma, 12-15 dicembre 2019
- "Le fake news, come comunicare in cardiologia, le parole corrette e quelle sbagliate"
- In quali pazienti oggi le linee guida consigliano una dimissione precoce dopo EP?
- Come iniziare la terapia con il sacubitril/valsartan in pazienti in classe III trattati con dosi massimali di ACE-inibitori, diuretici, beta bloccanti?
-
- I farmaci inotropo-positivi nello scompenso cardiaco avanzato

- *CONGRESSO APULIA HEART FAILURE 2020* "Aderenza Terapeutica: un obiettivo imprescindibile". - BARI 28-29 FEBBRAIO 2020
- *La gestione moderna dello scompenso cardiaco* "Facciamo il punto su Omega 3 e scompenso cardiaco" Virtual edition 5-6 giugno 2020
- *Cardiologia del Territorio* "Scompenso cardiaco valsartan/salcubitril i dati consolidati" Brescia 26 settembre 2020
- *PROGETTO HOT TOPICS* "I DOACS nella pratica clinica. Approprietezza prescrittiva: basso dosaggio e abuso delle dosi ridotte dei DOACS" Napoli 1-3 Ottobre 2020
- *Nel cuore di ... Roma* "Insufficienza cardiaca e comorbidità" Roma, 9-10 ottobre 2020
- *Nel cuore di ... Santa* "I care... woman heart" Web edition, 22-24 ottobre 2020
- *Scilla cuore XX edizione* " Il ruolo dell'ecocardiografia nello scompenso cardiaco" Virtual edition 26/10-17/11 2020
- *GIORNATE CARDIOLOGICHE PARTENOPEE VII EDIZIONE* "Il trattamento dello scompenso cardiaco nel paziente diabetico e non diabetico: quando le gliflozine? Virtual edition, 5-6 novembre 2020
- *81° Congresso Nazionale SIC* "Self-Care" nei pazienti con scompenso cardiaco" / I° Caso Clinico: Early Treatment subito dopo la diagnosi "Il paziente de novo" / Current trends in cardiovascular diseases in Italy in 2020 / I betabloccanti nella terapia dello scompenso: quali novità in epoca ARNI ed SGLT2-I / Nutrizione e sarcopenia: come preservare la massa muscolare nel paziente con scompenso cardiaco? / ANTIALDOSTERONICI: dal TOPCAT al FINEARTS-HF Roma, 17-20 Dicembre 2020
- *Nel cuore di ... Cagliari* "La terapia aggiornata dello scompenso cardiaco: la rivoluzione degli ARNI" Cagliari, 2-3 luglio 2021
- *52° CONGRESSO ANMCO* "Come le principali linee guida ESC del biennio 2019-2020 hanno modificato la pratica clinica" Rimini, 26-28 Agosto 2021
- *ESC CONGRESS 2021* Paradigm shift in heart failure treatment: are cardiologists ready to use gliflozins? Digital Experience 27-30 Agosto 2021
- *Grey Zones: Antialdosteronici e Stimolatori del GMP solubile Expert Opinions.* Bergamo, 30-2 Settembre/Ottobre 2021
- *Scilla Cuore* "Ruolo dei betabloccanti nello scompenso cardiaco: stato dell'arte" Scilla, 15-16 Ottobre 2021

- *Il cuore in Sardegna* “Lettura: Il futuro dello scompenso cardiaco e dei nuovi trattamenti” Via web, 8 Ottobre 2021
 - *Nel cuore di “Santa”* “Dalla prevenzione alla terapia dello scompenso cardiaco.. le gliflozine” Santa Margherita Ligure, 14-16 Ottobre 2021
 - *Cardiobat 2021* “SGLT-2 inibitori: una nuova classe di farmaci per la riduzione del rischio residuo” Trani, 29-30 Ottobre 2021
 - *Giornate Cardiologiche Partenopee VIII edizione: “Acidi grassi e Icosapent per la riduzione del rischio cardiovascolare”* Napoli, 23-24 Novembre 2021
 - *82° Congresso SIC* Roma, 9-12 Dicembre 2021
 - Approccio terapeutico selettivo dell'ipertensione arteriosa: dal sequenziamento del DNA alle differenze di genere
 - Tavola Rotonda "LA CARDIOLOGIA E IL GENERE FEMMINILE"
 - MODERATRICE: Il ruolo dell'e-health nel processo riabilitativo cardiovascolare in epoca Covid-19
 - Milrinone vs Dobutamina nel trattamento dello shock cardiogeno
 - Tavola Rotonda: TRIALS CLINICI E HIGHLIGHTS DELL'AHA 2021
-
- Vericiguat: la terapia emergente per la gestione e trattamento del paziente dopo un evento di riacutizzazione HfrEF
 - *Il cuore siamo noi - Il cuore delle donne vince anche sulla pandemia* “Cardiopatia ischemica e scompenso cardiaco: peculiarità dalla sintomatologia ai ritardi diagnostici”. Roma, 8 Marzo 2022
 - *Al cuore del diabete* “Insieme per migliorare la salute dei nostri pazienti”. Roma, 11-12 Marzo 2022
 - *Convegno E.C.M. The new heart failure guidelines: an update for clinical practice* “La(e) definizione(i) di insufficienza cardiaca e le classificazioni possibili”. Milano, 17-19 Marzo 2022
 - *X Corso superiore di aggiornamento in cardiologia* “Organizzazione di un ambulatorio moderno per lo scompenso: Come?”. Milano, 24-26 Marzo 2022
 - “Value Based Healthcare ecosystem in the management of chronic patients at cardiovascular risk: nuove soluzioni digitali al servizio del paziente”. Milano, 25-26 Marzo 2022
 - *Convegno E.C.M. “Controversie in tema di terapia anticoagulante: opinioni a confronto”*. Desenzano, 25-26 Marzo 2022

- *C-Share cardio share experience*. Brescia, 30 Marzo 2022 e 25 Maggio 2022
- *Apulia Heart Failure* “I limiti e vantaggi di una classificazione basata sulla frazione d’iezione”. Bari, 1-2 Aprile 2022
- *Masterclasses in the centers of expertise* “A smooth transition from hospital to outpatient care”. Brescia, 7-8 Aprile 2022
- *Nel Cuore di Santa* “Ipertensione e scompenso... un continuum terapeutico?”. Santa Margherita Ligure (GE), 7-9 Aprile 2022
- *Aggiornamenti in tema di terapia cardiovascolare* “Terapie anticoagulante della fibrillazione atriale non valvolare”. Gardone Riviera (BS), 9 Aprile 2022
- *Sicilia Cuore* “La malattia cardiovascolare nella donna: focus sulle differenze di sesso nella diagnosi e nella terapia”. Scilla (RC), 4 Maggio 2022
- *XXIV Congresso Nazionale GIEC – Come ripartire nella lotta alla morte improvvisa cardiaca dopo la pandemia* “Fumo alcol e stupefacenti: come possono danneggiare il cuore?”. Napoli, 12-14 Maggio 2022
- *Corso E.C.M.* “Come implementare la terapia RAASi nei pazienti con iperkaliemia – Share experience della real life”. Cavenago di Brianza (MB), 13 Maggio 2022
- *Nel cuore di... Cagliari* “Le linee guida dello scompenso cardiaco: luci e ombre”. Cagliari, 3-4 Giugno 2022
- *Grey Zones* “Incertezze sull’uso della DAPT e dei NOACs”. Bergamo, 9-11 Giugno 2022
- *Human Pixel* “Paziente obeso con sindrome metabolica, iperuricemia e diabete”. Milano, 16-17 Giugno 2022
- *FAD Sincrona SIC* “Cuore e GLP1/SGLT2: nuove vere prospettive terapeutiche?”. Via web, 21 Giugno 2022
- *XXIX Corso di Aggiornamento in Cardiologia* “Malattie cardiovascolari e medicina di genere: dalla fisiopatologia alla terapia”. Bormio (SO), 23-25 Giugno 2022
- *Congresso ACCD – Advances and Controversies in Cardiovascular Disease* “L’associazione farmacologica per il trattamento iniziale dell’ipertensione”. Pompei (NA), 30-2 Luglio 2022
- *Perspectives in Worsening Heart Failure*. Barcellona, 1-2 Luglio 2022

Standardized Curriculum Vitae

Savina Nodari, MD

Ai sensi degli art. 46 e 47 del DPR 28 dicembre 2000 n 445 lo scrivente dichiara di essere consapevole delle sanzioni penali previste dall'art. 76 del sopra indicato DPR, nel caso di dichiarazioni mendaci, falsità in atti, o esibizione di atto falso o contenente dati non più rispondenti a verità. Dichiara, quindi, sotto la propria responsabilità che quanto riportato corrisponde al vero.

La sottoscritta autorizza il trattamento dei dati personali ai sensi del D.Lgs. 196/03. In ogni modo i dati personali forniti potranno essere trattati dalla persona fisica o Ente che riceve il presente curriculum, esclusivamente per motivi legati della professione o per la comunicazione di informazioni inerenti l'ambito lavorativo

Brescia, 19/07/2022



